WO2014121087A1 - Antibodies comprising chimeric constant domains - Google Patents
Antibodies comprising chimeric constant domains Download PDFInfo
- Publication number
- WO2014121087A1 WO2014121087A1 PCT/US2014/014175 US2014014175W WO2014121087A1 WO 2014121087 A1 WO2014121087 A1 WO 2014121087A1 US 2014014175 W US2014014175 W US 2014014175W WO 2014121087 A1 WO2014121087 A1 WO 2014121087A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- amino acid
- recombinant polypeptide
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention concerns antibodies or antigen-binding proteins engineered with recombinant polypeptides comprising a chimeric constant region, more specifically including a chimeric hinge region in the heavy chain constant region.
- the present invention relates to antibodies and antigen-binding proteins comprising such recombinant polypeptides that reduce effector functions and provide an advantage for use in therapy.
- Immunoglobulins of the IgG class are attractive as therapeutic agents.
- IgGs exists as four subclasses in humans, lgG1 , lgG2, lgG3, and lgG4.
- the heavy chain constant (C H ) region of IgG comprises three domains, C H 1 , C H 2, C H 3, where C H 1 and C H 2 are linked by a hinge. Although the role of each subclass appears to vary between species, it is known that the heavy chain constant domain is responsible for various biological effector functions.
- the human IgG subclasses mediate a plethora of cellular immune responses through their interaction with Fey receptors (FcyRs), such as cell killing, complement activation, phagocytosis and opsonization.
- FeyRs Fey receptors
- researchers have made various mutations to the constant domains of IgGs and studied the resulting IgG/FcyR interaction (see e.g. Canfield and Morrison J Exp Med 73, 1483-1491 (1991 ); Chappel, M.S., et al. JSC 268(33), 25124-31 (1993); and Armour, K. L, et al. Eur J Immunol 29, 2613-24 (1999)).
- Fc dependent cytotoxic activity of human IgG antibodies requires binding of the Fc region of the antibody (which consists of at least a functional CH2 and CH3 domain) to an FcyR on the surface of an effector cell, such as a natural killer cell, an activated macrophage 8551
- Complement-mediated lysis can also be triggered by the interaction of the Fc region with various complement components.
- FcyR binding it has been suggested that several amino acid residues in the hinge region and in the C H 2 domain of the antibody are important (see Sarmay, G, et al. Mol Immunol 29, 633-9 (1992); Greenwood, J et al., Eur. J. Immunol, 23(5), 1098 (1993), Morgan, A. et al, Immunology, 86, 319 (1995), Stevenson, GT, Chemical Immunology, 65, 57-72 (1997)).
- the Fc receptor binding properties may be advantageous to engineer the Fc receptor binding properties so as to activate all, some, or none of the available effector mechanisms, without affecting the antibody's pharmacokinetic properties.
- the desired combination of therapeutic properties may not be available in the natural antibody repertoire.
- the design of antibodies with reduced effector function should be efficacious for example when the therapeutic objective is not to kill a target cell, but to block or activate a cell surface molecule on its surface without triggering cytotoxicity.
- Another setting in which reduced binding to Fc receptors could be desirable is when the antibody is bispecific, and its desired therapeutic properties arise from the different binding specificities.
- a common usage of bispecific antibodies is to combine a tumor targeting specificity with a T cell activating specificity in order to trigger tumor-specific T cell killing. In this case, if the Fc portion binds to an Fc receptor, then potentially that could trigger undesirable killing of cells bearing Fc receptors by T cells, or killing of T cells by Fc receptor-bearing cells such as natural killer cells or macrophages
- the antibodies, antigen-binding proteins and Fc-fusion proteins that are disclosed herein are engineered to have reduced binding to Fc receptors.
- One aspect of the invention provides a recombinant polypeptide comprising a chimeric Fc region, wherein the Fc region comprises a chimeric hinge comprising the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8).
- the invention also provides a recombinant polypeptide comprising a chimeric Fc region, wherein the Fc region comprises a chimeric hinge comprising the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).
- the recombinant polypeptide comprises a chimeric Fc region, wherein the Fc region comprises an lgG1 or lgG4 CH3 region, or a variant thereof. In other embodiments, the recombinant polypeptide comprises a chimeric Fc region, wherein the Fc region binds to FCYRI IA. In other aspects the recombinant polypeptide comprises a chimeric Fc region, wherein the Fc region binds to FcyRIIA and FcyRIIB.
- the invention provides a recombinant polypeptide comprising a chimeric Fc region, wherein the Fc region comprises chimeric hinge comprising an amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8) and the recombinant polypeptide binds to FcyRIIA.
- the invention provides a recombinant polypeptide comprising a chimeric Fc region, wherein the Fc region comprises a chimeric hinge comprising an amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9) and the recombinant polypeptide binds to FcyRIIA.
- a further aspect of the invention provides a recombinant polypeptide comprising a heavy chain constant (CH) region comprising, from N-terminus to C-terminus, a CH 1 domain, a chimeric hinge, a CH2 domain, and a CH3 domain
- the CH1 domain comprises a human lgG1 CH1 or a human lgG4 CH1 having at least the amino acid sequence DKKV or DKRV from positions 212 to 215 (EU numbering)
- the chimeric hinge comprises a human lgG1 or a human lgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering) and a human lgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering)
- the CH2 domain comprises a human lgG4 CH2 domain amino acid sequence from positions 237 to 340 (EU numbering)
- the CH3 domain comprises a human lgG1 or a human
- Some embodiments of the invention provide a recombinant polypeptide wherein the CH1 domain comprises a human lgG1 CH1 amino acid sequence (SEQ ID NO: 43), and the chimeric hinge comprises the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8). Still another embodiment of the invention provides a recombinant polypeptide wherein the CH1 domain comprises a human lgG4 CH1 amino acid sequence (SEQ ID NO: 44), and the chimeric hinge comprises the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).
- the CH1 domain comprises a variant of SEQ ID NO: 43 or 44.
- An aspect of the invention provides a recombinant polypeptide, wherein the polypeptide comprises N'-VD1-X1 n -Y1-Y2-X2-X3-C', wherein:
- N' is the N-terminus and C is the C-terminus of the polypeptide
- VD1 is an amino acid sequence comprising an antigen-binding domain
- X1 is an amino acid sequence comprising a domain selected from the group consisting of an lgG1 CH1 domain or a variant thereof, an lgG4 CH1 domain or a variant thereof, and at least positions 212-215 (EU numbering) of an lgG1 or lgG4 CH1 domain,
- Y1 comprises an amino acid sequence from positions 216-227 (EU numbering) of an lgG1 or lgG4 hinge region,
- Y2 comprises the human lgG2 lower hinge region amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering),
- X2 is an amino acid sequence comprising an lgG4 CH2 domain, or a variant thereof
- n 1 .
- X1 comprises the amino acid sequence DKKV (SEQ ID NO: 4), and Y1-Y2 comprises a chimeric hinge consisting of the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8).
- X1 comprises the amino acid sequence DKRV (SEQ ID NO: 5), and Y1-Y2 comprises a chimeric hinge consisting of the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).
- X1 comprises SEQ ID NO 43 or SEQ ID NO: 44.
- X2 comprises SEQ ID NO: 10.
- X3 comprises SEQ ID NO: 1 1 or SEQ ID NO: 12.
- X3 comprises SEQ ID NO: 41 or SEQ ID NO: 42.
- Another aspect of the invention provides a recombinant polypeptide wherein the heavy chain constant region (CH) region comprises an amino acid sequence at least 99% identical to any one of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 37 or SEQ ID NO: 38.
- CH heavy chain constant region
- the recombinant polypeptide is an antigen- binding protein.
- the recombinant polypeptide is a Fc-fusion protein, such as a receptor-Fc fusion protein.
- the recombinant polypeptide is an antibody.
- a further aspect of the invention provides a recombinant polypeptide, antigen-binding protein, Fc-fusion protein or antibody that exhibits decreased effector functions when compared to a corresponding recombinant polypeptide, antigen-binding protein, Fc-fusion protein or antibody comprising the wild-type lgG1 or lgG4 heavy chain constant region, at a concentration of at least 10 nM.
- the invention thus provides a recombinant polypeptide, antigen-binding protein, Fc-fusion protein or antibody having decreased binding, cytotoxic activity, and cellular proliferation.
- the invention further provides a recombinant polypeptide, antigen-binding protein, Fc-fusion protein or antibody that exhibits cytotoxic activity of less than about 50%, at a concentration of at least 10 nM or at least 100 nM.
- the invention also provides a recombinant polypeptide, antigen-binding protein, Fc-fusion protein or antibody that exhibits 8551
- cytotoxic activity of less than about 40%, or less than about 30%, or less than about 20%, or less than about 10%, or less than about 5%, or even undetectable, at a concentration of at least 10 nM or at least 100 nM.
- the recombinant polypeptide, antigen-binding protein, Fc- fusion protein or antibody exhibits CDC activity of less than about 50% cytotoxicity, or less than
- CDC activity is less than 50%, 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable, at a concentration of 100 nM.
- the recombinant polypeptide, antigen- binding protein, Fc-fusion protein or antibody exhibits ADCC activity of less than about 50% cytotoxicity, or less than cytotoxicity 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytotoxicity, as measured in an in vitro or ex vivo cell killing assay.
- ADCC activity is less than 50%, 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable ADCC activity, at a concentration of 100 nM.
- the recombinant polypeptide, antigen-binding protein, Fc- fusion protein or antibody exhibits ADCP activity of less than about 50% ADCP activity, or less than 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable ADCP activity, as measured in an in vitro or ex vivo cellular phagocytosis assay.
- ADCP activity is less than 50%, 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable ADCP activity, at a concentration of 100 nM.
- the invention further provides a recombinant polypeptide wherein the cytotoxic activity is at least about 10-fold less than the cytotoxic activity of a corresponding polypeptide comprising a wild-type lgG1 or wild-type lgG4 heavy chain constant region.
- the invention also provides a recombinant polypeptide wherein the cytotoxic activity is at least about 10-fold less, about 20-filed less, about 50-fold less, or about 100-fold less, or about 1000-fold less than the cytotoxic activity of a corresponding polypeptide comprising a wild- type lgG1 or wild-type lgG4 heavy chain constant region.
- An aspect of the invention provides a composition comprising the recombinant polypeptide.
- Another aspect of the invention provides a nucleic acid molecule encoding any one of the recombinant polypeptides of the invention.
- the invention further provides a nucleic acid molecule encoding a recombinant polypeptide of the invention, wherein the recombinant polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38 and SEQ ID NO: 37.
- the invention further provides a nucleic acid molecule comprising a nucleotide sequence having greater than 99% sequence identity to SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 32, or SEQ ID NO: 33.
- the invention also provides a nucleic acid molecule comprising a nucleotide sequence having greater than 99% sequence identity to SEQ ID NO: 36 or SEQ ID NO: 35.
- the invention also provides a nucleic acid molecule comprising a nucleotide sequence selected the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 36 and SEQ ID NO: 35.
- An aspect of the invention provides a vector comprising any one of the nucleic acid molecules of the invention.
- the invention further provides a vector wherein the nucleic acid molecule of the invention is operatively linked to an expression control sequence suitable for expression in a host cell.
- the invention also provides a vector of the invention wherein the expression control sequence comprises a promoter selected from the group consisting of SV40, CMV, CMV-IE, CMV-MIE, UbC, RSV, SL3-3, MMTV, Ubi and HIV LTR.
- the invention further provides a vector of the invention wherein the promoter is a CMV-MIE/TetO or CMV- MIE/Arc hybrid promoter.
- the invention also provides a vector of the invention comprising one or more selectable marker genes selected from the group consisting of bla, bis, BSD, bsr, Sh ble, hpt, tetR, tetM, npt, kanR and pac.
- Another aspect of the invention provides a cell comprising a nucleic acid of the invention.
- the invention further provides a cell comprising a vector of the invention.
- the invention further provides a cell comprising a nucleic acid of the invention, wherein the nucleic acid is integrated into the genome of the cell.
- the invention also provides a cell comprising a nucleic acid encoding a protein expression enhancer.
- the invention still further provides a cell comprising a nucleic acid encoding an XBP polypeptide.
- the cell is a eukaryotic cell.
- the cell is an animal cell.
- the cell is a mammalian cell.
- the cell is a CHO cell.
- the cell is a CHO-K1 cell.
- An aspect of the invention provides a method of making an antibody comprising a chimeric hinge region, said method comprising:
- step (a) transfecting a host cell with a nucleic acid molecule encoding the light chain of said antibody, said nucleic acid molecule comprising a nucleotide sequence encoding the V L region of a selected antigen-specific antibody and a nucleotide sequence encoding the constant C L region of an Ig, wherein said nucleotide sequence encoding the V L region of a selected antigen-specific antibody and said nucleotide sequence encoding the C L region of an Ig are operably linked together; (b) transfecting the host cell of step (a) with a nucleic acid molecule encoding the heavy chain of said antibody, said nucleic acid molecule comprising a nucleotide sequence encoding the V H region of a selected antigen-specific antibody and a nucleotide sequence encoding a constant C H region of a human Ig, wherein the nucleotide sequence encoding the C H region comprises the nucleotide sequence encoding S
- a method of making an antibody comprising a chimeric hinge region comprising:
- step (a) transfecting a host cell with a nucleic acid molecule encoding the light chain of said antibody, said nucleic acid molecule comprising a nucleotide sequence encoding the VL region of a selected antigen-specific antibody and a nucleotide sequence encoding the constant CL region of an Ig, wherein said nucleotide sequence encoding the VL region of a selected antigen-specific antibody and said nucleotide sequence encoding the CL region of an Ig are operably linked together; (b) transfecting the host cell of step (a) with a nucleic acid molecule encoding the heavy chain of said antibody, said nucleic acid molecule comprising a nucleotide sequence encoding the VH region of a selected antigen-specific antibody and a nucleotide sequence encoding a constant CH region of a human Ig, wherein the nucleotide sequence encoding the CH region comprises the chimeric hinge nucleotide sequence encoding S
- the method of making an antibody further comprises the steps of culturing the host cell of step (b) hereinabove, wherein the antibody is secreted into a cell culture medium; and isolating the antibody from the cell culture media.
- An aspect of the invention provides a method of making a receptor-Fc fusion protein comprising a chimeric hinge region, said method comprising:
- nucleotide sequence encoding a constant C H region of a human Ig wherein the nucleotide sequence encoding the C H region comprises the nucleotide sequence encoding SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38 or SEQ ID NO: 37, wherein said nucleotide sequence encoding the receptor protein and said nucleotide sequence encoding the C H region of said Ig are operably linked together; and (b) making said receptor-Fc fusion protein by expressing the nucleic acid molecule of (a) in said host cell.
- the method of making a receptor-Fc fusion comprises the steps of culturing the host cell of step (b) hereinabove, wherein the receptor- Fc fusion protein is secreted into a cell culture medium; and isolating the receptor-Fc fusion protein from the cell culture media.
- An aspect of the invention provides a method of making a receptor-Fc fusion protein comprising a chimeric hinge region, said method comprising:
- the method of making an antibody comprises:
- the heavy chains of the first and second heavy chain polypeptides each comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38 and SEQ ID NO: 37.
- the first cell culture further comprises a first cognate light chain of interest and the second cell culture further comprises a second cognate light chain of interest, wherein the first and second cognate light chains are covalently bound to the first and second heavy chain polypeptides and are thus recovered.
- heavy chains of the first and second heavy chain polypeptides each comprise a chimeric hinge amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 9.
- the invention provides a method of making an antibody comprising a first single chain variable fragment-Fc (scFv-Fc) produced in a first cell culture, and a second scFv-Fc produced in a second cell culture, wherein the Fc of the first and second scFv-Fc each comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38 and SEQ ID NO: 37, combining the first and second cell cultures or the supernatants thereof, and recovering or isolating the first and second scFv-Fc in heterodimeric form.
- scFv-Fc single chain variable fragment-Fc
- the first and second scFv-Fc are secreted into the cell culture medium (e.g. supernatant), and the method comprises combining the first and second cell culture media, and recovering or isolating the heterodimeric protein.
- the Fc of the first and second scFv-Fc each comprises a chimeric hinge amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 9.
- the host cell is selected from the group consisting of CHO, COS, retinal cell, Vero, CV1 , 293, MDCK, HaK, BHK, HeLa, HepG2, WI38, MRC 5, Colo25, HB 8065, HL-60, Jurkat, Daudi, A431 (epidermal), CV-1 , U937, 3T3, L cell, C127 cell, SP2/0, NS-0, MMT cell, tumor cell, a cell line derived from any of the aforementioned cells, and a PER.C6® cell.
- Another aspect of the invention provides a bispecific antibody comprising:
- the heavy chain of (a) or (b) or both (a) and (b) comprises the heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, or SEQ ID NO: 31 , or wherein the heavy chain of (a) or (b) or both (a) and (b) comprises the chimeric hinge region comprising the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9.
- a further aspect of the invention provides a bispecific antibody of the invention comprising:(a) a first heavy chain comprising a first heavy chain constant region comprising SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, or SEQ ID NO: 31 , and (b) a second heavy chain comprising a second heavy chain constant region comprising SEQ ID NO: 38 or SEQ ID NO: 37. 8551
- FIG. 1 shows the corresponding amino acid numbering conventions for the hinge region of hlgG1 , hlgG2 and hlgG4.
- FIG. 2 illustrates hinge amino acids used in the construction of chimeric hinge regions and the corresponding amino acid conventions.
- FIG. 3 Amino acid sequence of the human lgG1 heavy chain constant region including CH1 , hinge, CH2 and CH3 domains as described as IGHG1 in UniProtKB/Swiss- Prot Accn. No. P01857 (SEQ ID NO: 13).
- FIG. 4 Amino acid sequence of the human lgG2 heavy chain constant region including CH1 , hinge, CH2 and CH3 domains as described as IGHG2 in UniProtKB/Swiss- Prot Accn. No. P01859 (SEQ ID NO: 14).
- FIG. 5 Amino acid sequence of the human lgG4 heavy chain constant region including CH1 , hinge, CH2 and CH3 domains as described as IGHG4 in UniProtKB/Swiss- Prot Accn. No. P01861 (SEQ ID NO:15).
- FIG. 6 Single-parameter histograms showing antibody binding (% of Max) to antigen on Jurkat cells in a fluorescent binding assay.
- FIG 6A Background fluorescence was measured for control assays, i.e. Jurkat cells incubated with secondary antibody only (sec) and unstained Jurkat cells.
- FIG. 7 Dose-response curve depicting chimeric hinge antibody ability to bind U937 cells.
- Half-maximal concentration (EC 50 ) values with respect to binding (mean fluorescence intensity) are given.
- Control antibody 1 wt lgG1 C H ;
- Antibody 2 slgG1 ;
- Control Ab 2 wt lgG4 C H ;
- Antibody 1 slgG4.
- FIG. 8 Dose-response curve depicting chimeric hinge antibody lack of cytotoxicity with respect to U937 cells in the presence of activated PBMCs (T cells). Half-maximal concentration (EC 50 ) values with respect to % cytotoxicity are reflected.
- Control antibody 1 wt lgG1 C H ;
- Antibody 1 slgG4;
- Control Ab 2 wt lgG4 C H ;
- Antibody 2 slgG1 ;
- Control Ab 3 wt lgG1 C H .
- FIG. 9 Dose-response curve depicting the half-maximal concentration (EC 5 o) with respect to cell viability in a PBMC proliferation assay.
- FIG 10. Dose-response curves depicting lack of CDC activity with respect to Daudi (FIG 10A) and Raji (FIG. 10B) cells in the presence of antibodies having wild-type or chimeric hinge C H regions.
- Control antibody 5 Bispecific Ab with wt lgG1 C H ;
- Antibody 3 slgG1 * ;
- Antibody 4 slgG1 * ;
- lgG1 Isotype Control nonspecific Ab with wt lgG1 C H .
- FIG 1 Dose-response curves depicting lack of ADCC activity with respect to Daudi (FIG 1 1 A) and Raji (FIG. 1 1 B) cells in the presence of antibodies having wild-type or chimeric hinge C H regions.
- Control antibody 5 Bispecific Ab with wt lgG1 C H ;
- Antibody 3 slgG1 * ;
- Antibody 4 slgG1 * ;
- lgG1 Isotype Control nonspecific Ab with wt lgG1 C H .
- immunoglobulin refers to a class of structurally related glycoproteins consisting of two pairs of polypeptide chains, one pair of light (L) chains and one pair of heavy (H) chains, which may all four be inter-connected by disulfide bonds.
- L light
- H heavy
- each heavy chain typically comprises a heavy chain variable region (abbreviated herein as V H or VH) and a heavy chain constant region (C H or CH).
- the "heavy chain constant region”, as used herein, typically comprises three domains, C H 1 , C H 2, and C H 3, whereas the C H 1 and C H 2 domains are linked by a hinge, or a functional fragment thereof.
- Each light chain typically comprises a light chain variable region (abbreviated herein as V L or VL) and a light chain constant region.
- V L or VL light chain variable region
- the light chain constant region typically comprises one domain (C L ).
- _ regions may be further subdivided into regions of hypervariability (or hypervariable regions which may be hypervariable in sequence and/or form of structurally defined loops), also termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- Each V H and V L is typically composed of three CDRs and four FRs, arranged from amino-terminus (N-terminus) to carboxy-terminus (C-terminus) in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mol. Biol. 196, 901-917 (1987)).
- the numbering of amino acid residues in this region is according to IMGT, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991 ), or by the EU numbering system of Kabat (also known as "EU numbering” or "EU index”), e.g., as in Kabat, E.A. et al. Sequences of Proteins of Immunological interest. 5 th ed. US Department of Health and Human Services, NIH publication No. 91-3242 (1991 ).
- antibody refers to an immunoglobulin molecule, or a derivative thereof, which has the ability to specifically bind to an antigen.
- the variable regions of the heavy and light chains of the immunoglobulin molecule contain a binding domain that interacts with an antigen as outlined above under "immunoglobulin".
- An antibody may also be a bispecific antibody, diabody, or similar molecule (see for instance PNAS USA 90(14), 6444-8 (1993) for a description of diabodies). Further, it has been shown that the antigen-binding function of an antibody may be performed by fragments of a full-length 8551
- antigen-binding proteins may be monospecific or multispecific (e.g., bispecific).
- binding molecules or fragments encompassed within the term "antibody” include, but are not limited to (i) a Fab' or Fab fragment, a monovalent fragment consisting of the V
- human antibody is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
- the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site- specific mutagenesis in vitro or during gene rearrangement or by somatic mutation in vivo).
- a multispecific antigen-binding fragment of an antibody (e.g., a bispecific antibody) will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen.
- Any multispecific antibody format, including bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present invention using routine techniques available in the art.
- the two domains of the Fv fragment, V L and V H are coded for by separate genes, they may be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain antibodies or single chain Fv (scFv), see for instance Bird et al., Science 242, 423-426 (1988) and Huston et al., PNAS USA 85, 5879-5883 (1988)).
- single chain antibodies are encompassed within the term "antibody” unless otherwise noted or clearly indicated by context.
- polypeptides are generally included within the meaning of antibody, they collectively, and each independently, are unique features of the present invention, exhibiting different biological properties and utility. These and other antibody fragments and recombinant polypeptides that are useful in the context of the present invention are discussed further 8551
- antibody also includes polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides, such as chimeric antibodies and humanized antibodies, and any antibody fragments retaining the ability to specifically bind to the antigen (antigen-binding fragments or molecules) provided by any known technique, such as enzymatic cleavage, peptide synthesis, and recombinant techniques.
- An antibody as generated can possess any Ig isotype or combination thereof. Any scFv may be fused to the heavy chain constant regions of the invention by known techniques.
- bispecific formats that can be used in the context of the present invention include, without limitation, e.g., scFv-based bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-lg, Quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes, etc.), CrossMab, CrossFab, (SEED)body, dual acting Fab (DAF)-lgG, and Mab2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1- 11 , and references cited therein, for a review of the foregoing formats).
- Bispecific antibodies can also be constructed using peptide/nucleic acid conjugation, e.g., wherein unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody- oligonucleotide conjugates which then self-assemble into multimeric complexes with defined composition, valency and geometry.
- peptide/nucleic acid conjugation e.g., wherein unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody- oligonucleotide conjugates which then self-assemble into multimeric complexes with defined composition, valency and geometry.
- FIG. 1 For exemplary multispecific formats, can be used in the context of the present invention include, without limitation, e.g., involving a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein, wherein such second antigen-binding domains are capable of activating and internalizing the effector protein, e.g. a receptor.
- a first antigen-binding domain that specifically binds a target molecule
- FIG. 1 See U.S. Application Publication. No. 2013/0243775A1 , published on September 19, 2013, which is incorporated by reference.
- Recombinant proteins may be produced by standard molecular biology techniques well known to the skilled artisan (see e.g., Sambrook, J., E. F. Fritsch And T. Maniatis. Molecular Cloning: A Laboratory Manual, Second Edition, Vols 1 , 2, and 3, 1989; Current Protocols in Molecular Biology, Eds. Ausubel et al., Greene Publ. Assoc., Wiley Interscience, NY).
- CDR complementarity determining regions
- Ig immunoglobulin
- a CDR can be encoded by, for example, a germline sequence or a rearranged or unrearranged sequence, and, for example, by a naive or a mature B cell or a T cell.
- CDRs can be encoded by two or more sequences (e.g., germline sequences) that are not contiguous (e.g., in an unrearranged nucleic acid sequence) but are contiguous in a B cell nucleic acid sequence, e.g., as the result of splicing or connecting the sequences (e.g., V-D-J recombination to form a heavy chain CDR3).
- sequences e.g., germline sequences
- a B cell nucleic acid sequence e.g., as the result of splicing or connecting the sequences (e.g., V-D-J recombination to form a heavy chain CDR3).
- antigen-binding domain is the amino acid sequence of a heavy chain or light chain capable of selectively recognizing and binding to antigen with a K D at least in the micromolar range.
- the antigen-binding domain of the invention includes at least one CDR.
- variable domain includes an amino acid sequence of an immunoglobulin light or heavy chain (modified as desired) that comprises the following amino acid regions, in sequence from N-terminal to C-terminal (unless otherwise indicated): FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
- a "variable domain” includes an amino acid sequence capable of folding into a canonical domain (VH or VL) having a dual beta sheet structure wherein the beta sheets are connected by a disulfide bond between a residue of a first beta sheet and a second beta sheet.
- heavy chain or "immunoglobulin (Ig) heavy chain
- Ig heavy chain constant region sequence from any organism, and unless otherwise specified includes a heavy chain variable domain.
- Heavy chain variable domains include three heavy chain CDRs and four FR regions, unless otherwise specified. Fragments of heavy chain variable domains include CDRs, or both CDRs and FRs.
- a typical heavy chain constant region has, following the variable domain (from N-terminal to C-terminal), a CH1 domain, a hinge, a CH2 domain, and a CH3 domain.
- a functional fragment of a heavy chain in an antigen-binding protein includes a fragment that is capable of specifically recognizing an antigen (e.g., recognizing the antigen with a K D in the micromolar, nanomolar, or picomolar range), that is capable of being expressed in and secreted from a cell, and that comprises at least one CDR.
- a functional fragment of a heavy chain constant region includes at least an Fc domain or fragment thereof.
- Fc-containing protein includes antibodies, bispecific antibodies, antibody-binding fragments, trap molecules and other receptor-Fc fusion proteins, and other binding proteins that comprise at least a functional portion of an immunoglobulin CH2 and CH3 region, such as ligand-Fc fusion proteins.
- a "functional portion” refers to a CH2 and CH3 region that can bind an Fc receptor e.g., an FcyR, (namely FcyRI (CD64), FcyRlla 8551
- any Fc-containing protein may be engineered to comprise a chimeric heavy chain constant region or fragment as described herein.
- Fc-fusion proteins and specifically “receptor-Fc fusion proteins” includes recombinant proteins engineered to contain a functional Fc fragment as described herein.
- a "receptor-Fc fusion protein” includes a chimeric protein comprising an amino acid sequence of a receptor protein fused to an amino acid sequence of an Fc domain of Ig.
- receptor proteins used in fusion proteins are known in the art (see e.g. Klinkert, et al. J Neuroimmunol. 72(2): 163-8 (1997); Milligan, G., et al. Curr Pharm Des. 10(17): 1989-2001 (2004); and Schwache D, and Muller-Newen G, Eur J Cell Biol. 91 (6- 7):428-34 (2012), doi: 10.1016/j.ejcb.201 1 .07.008. Epub 201 1 Sep 29).
- receptor-Fc fusion proteins are encoded by a nucleotide sequence encoding a receptor protein fused to a nucleotide sequence of a chimeric heavy chain constant region as described herein.
- the nucleotide sequence of the receptor protein encodes for the ligand-binding domain or the extracellular domain of the receptor.
- the nucleotide sequence of the receptor protein encodes for the extracellular domain of the receptor and the transmembrane domain of the receptor.
- Receptor-Fc fusion proteins are also exemplified in US20090137416 A1 .
- FASTR Flow cytometry-based autologous secretion trap
- Light chain includes an immunoglobulin light chain constant region sequence from any organism, and unless otherwise specified includes human kappa and lambda light chains.
- Light chain variable (VL) domains typically include three light chain CDRs and four framework (FR) regions.
- FR framework
- a full-length light chain includes, from amino terminus to carboxyl terminus, a VL domain that includes FR1 -CDR1 -FR2-CDR2-FR3-CDR3-FR4, and a light chain constant domain.
- polypeptides of the invention comprise amino acid sequences that are derived from an immunoglobulin domain.
- a polypeptide or amino acid sequence "derived from” a designated protein refers to the origin of the polypeptide.
- hinge is intended to include the region of consecutive amino acid residues that connect the C-terminus of the C H 1 to the N-terminus of the C H 2 domain of an immunoglobulin. Several amino acids of the N-terminus of the C H 2 domain, which are coded by the C H 2 exon, are also considered part of the "lower hinge".
- amino acids of the hinge region of lgG1 , lgG2 and lgG4 have been characterized as comprising 12-15 consecutive amino acids encoded by a distinct hinge exon, and several N-terminal amino acids of the C H 2 domain (encoded by the C H 2 exon) (Brekke, O.H., et al. Immunology Today 16(2):85-90 (1995)).
- lgG3 comprises a hinge region consisting of four segments: one upper segment resembling the hinge region of lgG1 , and 3 segments that are identical amino acid repeats unique to lgG3.
- amino acids of the hinge region for human lgG1 , lgG2 and lgG4 have been identified herein by the EU numbering system of Kabat (Kabat, E.A. et al., Sequences of Proteins of Immunological interest. 5 th ed. US Department of Health and Human Services, NIH publication No.
- an "upper hinge” region is intended to include amino acid residues from positions 216 to 227 according to EU numbering (amino acid residues from positions 226 to 240 according to Kabat numbering) (see also Figure 2).
- a “lower hinge” region is intended to include amino acid residues from positions 228 to 236 according to EU numbering (amino acid residues from positions 241 to 249 according to Kabat numbering) (see also Figure 2).
- chimeric means composed of parts of different origin.
- the phrase "chimeric protein” includes a first amino acid protein linked to a second amino acid protein that is not normally linked in nature.
- the amino acid sequences may normally exist as separate proteins or in a different arrangement on the same protein, and are brought together in a fusion polypeptide in a new arrangement.
- Chimeric proteins may be created by various methods known in the art, e.g. by chemical synthesis or by creating a polynucleotide that encodes for amino acids of the chimeric protein in the desired arrangement.
- Exemplary chimeric proteins include the chimeric hinge sequences connecting heavy chain domains of IgG, and the fusion proteins engineered to make the human antibodies, antigen-binding proteins and receptor-Fc fusion proteins of the present invention.
- the chimeric proteins disclosed herein were designed to minimize the creation of immunogenic epitopes in the junctions, e.g. compared to a wild-type IgG Fc region or domain.
- the engineered proteins of the invention therefore have reduced immunogenicity, and display reduced binding to Fc receptors, as well as reduced to no effector functions.
- chimeric hinge is intended to include a chimeric protein comprising a first amino acid sequence derived from the hinge region of one Ig molecule and a second amino acid sequence derived from the hinge region of a different class or subclass of Ig molecule.
- exemplary chimeric hinges of the present invention comprise a first amino acid sequence, or an "upper hinge” sequence, derived from a human lgG1 or human lgG4 hinge region, and a second amino acid sequence, or a "lower hinge” sequence, derived from a human lgG2 hinge region.
- the first or "upper hinge” sequence comprises amino acid residues from positions 216 to 227 according to EU numbering.
- the second or "lower hinge” sequence comprises amino acid residues from positions 228 to 236 according to EU numbering.
- humanized antibody is intended to include antibodies in which CDR sequences are derived from the germline of another mammalian species, such as a mouse, and have been grafted onto human framework sequences.
- Humanized monoclonal antibodies may be generated by a hybridoma which includes a B lymphocyte 8551
- variable regions can be "reshaped” or “humanized” by grafting CDRs derived from nonhuman antibody on the FRs present in the human antibody to be modified.
- humanized antibodies preserve all CDR sequences (for example, a humanized mouse antibody which contains all six CDRs from the mouse antibodies).
- humanized antibodies have one or more CDRs (one, two, three, four, five, or six) which are altered with respect to the original antibody, which are also termed one or more CDRs "derived from" one or more CDRs from the original antibody.
- Humanized antibodies may refer to chimeric molecules prepared using recombinant techniques.
- chimeric antibodies comprising human variable regions linked to murine constant regions, such as those produced by cell lines generated by a VELOCIMMUNE mouse, are humanized by replacing the murine constant region for a human constant region comprising SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38 or SEQ ID NO:37.
- monoclonal antibody or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition.
- a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
- murine monoclonal antibody refers to antibodies displaying a single binding specificity which have variable and constant regions derived from murine or mouse germline immunoglobulin sequences.
- binding in the context of the binding of an antibody, Ig, antibody-binding fragment, or Fc-containing protein to either, e.g., a predetermined antigen or to a FcR, typically refers to an interaction or association between a minimum of two entities, or molecular structures, such as an antibody-antigen interaction, or an Fc-containing 8551
- Fc-containing protein is an antibody, Ig, antibody-binding fragment, or Fc-fusion protein, e.g. receptor-Fc fusion).
- binding affinity typically corresponds to a K D value of about 10 "7 M or less, such as about 10 "8 M or less, such as about 10 "9 M or less when determined by, for instance, surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using the antigen or FcR as the ligand and the antibody, Ig, antibody-binding fragment, or Fc- containing protein as the analyte (or antiligand).
- SPR surface plasmon resonance
- the antibody or other binding protein binds to the predetermined antigen or receptor with an affinity corresponding to a K D value that is at least ten-fold lower, such as at least 100 fold lower, for instance at least 1 ,000 fold lower, such as at least 10,000 fold lower, for instance at least 100,000 fold lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein).
- a non-specific antigen e.g., BSA, casein
- K D refers to the dissociation equilibrium constant of a particular antibody-antigen interaction, or the dissociation equilibrium constant of an antibody, Ig, antibody-binding fragment, or Fc-containing protein to an FcyR.
- K D binding affinity
- k d (sec 1 or 1/s), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction, or the dissociation rate constant of an antibody, Ig, antibody-binding fragment, or Fc-containing protein to an FcyR. Said value is also referred to as the k 0ff value.
- k a (M ⁇ 1 x sec “1 or 1/M), as used herein, refers to the association rate constant of a particular antibody-antigen interaction, or the association rate constant of an antibody, Ig, antibody-binding fragment, or Fc-containing protein to an FcyR.
- K A (M ⁇ 1 or 1/M), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction, or the association equilibrium constant of an antibody, Ig, antibody-binding fragment, or Fc-containing protein to an FcyR.
- the association equilibrium constant is obtained by dividing the k a by the k d .
- EC 50 refers to the half maximal effective concentration, which includes the concentration of an antibody which induces a response halfway between the baseline and maximum after a specified exposure time.
- the EC 50 essentially represents the concentration of an antibody where 50% of its maximal effect is observed. Thus, reduced binding is observed with an increased EC 50 , or half maximal effective concentration value.
- decreased binding can be defined as an increased EC 50 antibody concentration which enables binding to the half-maximal amount of target cells.
- decreased cytotoxic activity can be defined as an increased EC 50 antibody concentration which enables lysis of the half-maximal amount of target cells.
- decreased proliferation can be defined as an increased EC 50 antibody concentration which enables proliferation of the half-maximal amount of target cells.
- bispecific antibody includes antibodies that are specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, e.g., Tutt et al. (1991 J J. Immunol. 147:60-69.
- the human antibodies can be linked to or co-expressed with another functional molecule, e.g., another peptide or protein.
- an antibody or fragment thereof can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment, to produce a bispecific or a multispecific antibody with a second binding specificity.
- bispecific antibody also includes two antibodies of different specificity.
- the heavy chain of at least one of the Ig heavy chains in a bispecific antibody is modified to comprise a chimeric heavy chain constant region comprising a recombinant polypeptide of the invention.
- at least one of the heavy chains is modified in the CH3 domain resulting in a differential affinity for the bispecific antibody for an affinity reagent, such as Protein A, for ease of isolation.
- At least one of the heavy chains in such bispecific antibody comprises an amino acid modification at i) 95R or ii) 95R and 96F in the IMGT numbering system (95R and 96F correspond to 435R and 436F in the EU numbering system), for example SEQ ID NO: 37 and SEQ ID NO: 38.
- a multispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen.
- Any multispecific antibody format may be adapted for use in the context of an antigen-binding protein or antibody of the present invention using routine techniques available in the art.
- isotype refers to the immunoglobulin class (for instance, lgG1 , lgG2, lgG3, lgG4, IgD, IgA, IgE, or IgM) that is encoded by heavy chain constant region genes.
- epitope means an antigenic determinant capable of specific binding to an antibody.
- Epitopes usually consist of surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former, but not the latter, is lost in the presence of denaturing solvents.
- the epitope may comprise amino acid residues directly involved in the binding (also called immunodominant component of the epitope) and other amino acid residues, which are not directly involved in the binding, such as amino acid residues which are effectively blocked by the specific antigen binding peptide (in other words, the amino acid residue is within the footprint of the specific antigen binding peptide).
- a humanized antibody is "derived from" a particular germline sequence if the antibody is obtained from a system using human immunoglobulin sequences, for instance by immunizing a transgenic mouse carrying human immunoglobulin genes or by screening a human immunoglobulin gene library, and wherein the selected human antibody V domain sequence is at least 90%, such as at least 95%, for instance at least 96%, such as at least 97%, for instance at least 98%, or such as at least 99% identical in amino acid V domain sequence to the amino acid sequence encoded by the germline immunoglobulin gene.
- a human antibody derived from a particular human germline sequence will display no more than 20 amino acid differences, e.g. no more than 10 amino acid differences, such as no more than 9, 8, 7, 6 or 5, for instance no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene.
- transgenic non-human animal refers to a non-human animal having a genome comprising one or more human heavy and/or light chain transgenes or transchromosomes (either integrated or non-integrated into the animal's natural genomic DNA) and which is capable of expressing fully human antibodies.
- Mice that express antibodies that are fully human, or partly human and partly mouse, have previously been reported.
- a transgenic mouse can have a human light chain transgene and either a human heavy chain transgene or human heavy chain transchromosome, such that the mouse produces human antibody when immunized with target antigen and/or cells 8551
- the human heavy chain transgene may be integrated into the chromosomal DNA of the mouse, as is the case for transgenic mice, for instance HuMAb mice, such as HCo7 or HCol2 mice, or the human heavy chain transgene may be maintained extrachromosomally, as is the case for transchromosomal KM mice as described in WO02/43478.
- transgenic and transchromosomal mice are capable of producing multiple isotypes of human monoclonal antibodies to a given antigen (such as IgG, IgA, IgM, IgD and/or IgE) by undergoing V-D-J recombination and isotype switching.
- VELOCIMMUNE® genetically engineered mice comprise a replacement of unrearranged V(D)J gene segments at endogenous mouse loci with human V(D)J gene segments.
- VELOCIMMUNE® mice express chimeric antibodies having human variable domains and mouse constant domains (see, e.g., U.S. Pat. No. 7,605,237). Most other reports concern mice that express fully human antibodies from fully human transgenes in mice that have disabled endogenous immunoglobulin loci.
- the VELOCIMMUNE® mouse includes, in part, having a genome comprising human variable regions operably linked to endogenous mouse constant region loci such that the mouse produces antibodies comprising a human heavy chain variable region and a mouse heavy chain constant region in response to antigenic stimulation.
- the DNA encoding the variable regions of the heavy chains of the antibodies can be isolated and operably linked to DNA encoding the human heavy chain constant regions of the invention. The DNA can then be expressed in a cell capable of expressing the fully human heavy chain of the antibody.
- a transgenic, nonhuman animal can also be used for production of antibodies against a specific antigen by introducing into the animal genes encoding such specific antibody, for example by operatively linking the genes to a gene which is expressed in the milk of the animal.
- effector functions is intended to include the functional capabilities imparted by an Fc-containing protein upon binding to an FcyR. Without being bound to any one theory, formation of an Fc/FcyR complex recruits a variety of effector cells to sites of bound antigen, typically resulting in diverse signaling events within the cells and important subsequent immune responses.
- effectorless polypeptide refers to a recombinant polypeptide, antigen- binding protein or antibody which has altered or reduced effector function as compared to a corresponding recombinant polypeptide, antigen-binding protein or antibody comprising a wild-type heavy chain constant region of the lgG1 or lgG4 isotype.
- 8551
- the effector function that is reduced or altered is a cytotoxic effector function, e.g., cytotoxicity, complement-dependent cytotoxicity (CDC), antibody-dependent cytotoxicity (ADCC), or antibody-dependent cellular phagocytosis (ADCP).
- cytotoxic effector function e.g., cytotoxicity, complement-dependent cytotoxicity (CDC), antibody-dependent cytotoxicity (ADCC), or antibody-dependent cellular phagocytosis (ADCP).
- the effector function that is reduced or altered is complement-dependent cytotoxicity.
- the effector function that is reduced or altered is antibody-dependent cytotoxicity.
- the effector function that is reduced or altered is cellular proliferation.
- Fc receptors which bind the Fc region of an antibody in the constant domain (specifically, the CH2 and CH3 domain) of a typical immunoglobulin.
- Fc receptors There are a number of Fc receptors which are specific for the different classes of immunoglobulins, i.e. IgG, IgE, IgA, IgM, and IgD.
- the human IgG Fc receptor family is divided into three groups: FcyRI (CD64), which is capable of binding IgG with high affinity, FcyRII (CD32) and FcyRIII (CD16) both of which are low affinity receptors.
- FcyR subclass is encoded by two or three genes, and alternative RNA splicing leads to multiple transcripts, hence, a broad diversity in FcyR isoforms exists (e.g. FcyRIA (CD64; FCGR1A), FcyRIB (CD64; FCRG1 B), FcyRIIA (CD32; FCGR2A), FcyRIIB (CD32; FCGR2B), FcyRIIC (CD32; FCGR2C), FcyRIIIA (CD16a; FCGR3A), and FcyRIIIB (CD16b; FCGR3B)).
- FcyRIA CD64; FCGR1A
- FcyRIB CD64; FCRG1 B
- FcyRIIA CD32; FCGR2A
- FcyRIIB CD32; FCGR2B
- FcyRIIC CD32; FCGR2C
- FcyRIIIA CD16a; FCGR3A
- FcyRIIIB CD16b;
- FcRn or neonatal Fc receptor
- Fc receptor transporter alpha, or FCGRT
- Fc receptors are expressed on a variety of cells, including, e.g., B cells, monocytes, dendritic cells, neutrophils, and certain lymphocytes.
- B cells e.g., B cells
- monocytes e.g., monocytes
- dendritic cells e.g., neutrophils
- neutrophils e.g., neutrophils, and certain lymphocytes.
- U937 cells a human monocyte cell line
- FcyRIIA see e.g., Jones, et al. J Immunol 135(5):3348-53 (1985); and Brooks, et al. J Exp Med 170:1369-85 (October 1989)).
- Binding of an Ig Fc to its receptor brings these effector cells to sites of the bound antigen, resulting ultimately in a variety of signaling and immune responses, including B cell activation, inflammatory responses, cytotoxic responses, and phagocytic responses. As such, reduced or altered binding of an Ig Fc to its receptor may result in reduced effector functions.
- antibody-dependent cellular cytotoxicity means an activity to damage a target cell when an 8551
- FCY receptor-bearing cell (an immune cell or the like) binds to an Fc portion of a specific antibody through the Fcy receptor, when the specific antibody has attached to a cell-surface antigen of the target cell.
- ADCC is a mechanism by which Fc receptor-positive effector cells can lyse target cells that have adherent antigen-specific molecule.
- the ADCC activity can be evaluated by a number of well-known methods, including measuring the fluorescent intensity using a fluorescent dye such as calcein AM (Wako Pure Chemical Industries, Ltd., 349-07201 ).
- the cytotoxic activity (%) can be calculated, using the obtained values, according to the equation: (A-C)/(B-C)x100, wherein A is a fluorescent value in each sample, B is an average fluorescent value of the cells lysed and released into a medium with Nonidet P-40 having a final concentration of 1 %, and C is an average fluorescent value when only the medium was added.
- ADCP antibody-dependent cellular phagocytosis
- ADCP may be an important in vivo mechanism for killing tumor cells.
- ADCP can be measured by two-color fluorescence flow cytometry methods, for example methods utilizing, e.g. PKH2 (green fluorescent dye) and phycoerythrin-conjugated (red) monoclonal antibodies against different cell surface proteins to differentiate the test cells, thus determining phagocytic activity and rate of phagocytosis.
- Therapeutic strategies that selectively activate FcyRlla relative to FcyRllb may enhance macrophage phagocytic activity (Richards, JO, et al. 2008 Mol Cancer Ther 7(8):2517-27).
- CDC complement-directed cytotoxicity
- the CDC activity is measured by well-known methods, for example the target cells, antibody, and complement solution (such as baby rabbit complement (Cedarlane Technologies) are incubated and are allowed to react, according to standard protocols (NIAID Manual of Tissue Typing Techniques 1979- 1980, Edited by J.G. Ray, NIH Publication No. NIH-83-545.)
- the cytotoxic activity can be calculated in the same manner as the measurement of the ADCC activity.
- the cytotoxic activity can also be measured using a fluorescent dye (such as calcein) or radioactive dyes similarly to the above with respect to ADCC.
- cytotoxicity or "direct cytotoxicity” includes any cytotoxic activity including that which is independent of NK cells. Cytotoxicity may be measured by techniques well known in the art, for example, determining cell lysis or cell death, i.e. apoptosis. Direct cell lysis, or cell killing, can be evaluated by a number of well-known methods, including measuring the fluorescent intensity using calcein and calculating an average fluorescent value in a similar fashion as described with respect to ADCC hereinabove. Alternatively, a 8551
- cytotoxic molecule such as an antibody
- Apoptosis is characterized by well defined cytological and molecular events including a change in the refractive index of the cell, cytoplasmic shrinkage, nuclear condensation and cleavage of DNA into regularly sized fragments.
- the apoptotic activity is measured using standard methods of determining dying and/or dead cells. In order to measure apoptosis, cytotoxicity assays can be employed.
- These assays may be radioactive or non-radioactive assays that measure increases in plasma membrane permeability, since dying cells become leaky, colorimetric assays may be employed that measure reduction in the metabolic activity of mitochondria based on the knowledge that mitochondria in dead cells cannot metabolize dyes, while mitochondria in live cells can.
- Bioluminescent cytotoxicity assays e.g. CytoTox- GloTM, Promega
- Protease activity is considered a robust enzymatic cell death marker, and may be used as a ratiometric measurement of viable and dead cells (Niles, A.L., et al. Anal Biochem, 366(2): 197-206, 15 July 2007).
- later stages of apoptosis, such as activation of caspases can be measured in populations of cells or in individual cells.
- measurement of release of cytochrome C and AIF into cytoplasm by mitochondria or fragmentation of chromosomal DNA can be determined.
- Terminal deoxynucleotidyl transferase dUTP nick end labeling TUNEL is a common method for detecting DNA fragmentation that results from apoptotic signaling cascades.
- the assay relies on the presence of nicks in the DNA which can be identified by terminal deoxynucleotidyl transferase, an enzyme that will catalyze the addition of bromolated dUTPs that are secondarily detected with a specific labelled antibody.
- Cytotoxicity may be complement-directed, or antibody-directed, or directly associated with the binding of a cytotoxic molecule or cell.
- antibodies of the invention exhibit cytotoxicity of less than 20% cytolysis (i.e. % cytotoxicity), or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytolysis (cytotoxicity), as measured in an in vitro or ex vivo cell killing assay. In certain embodiments, antibodies of the invention exhibit less than 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytotoxicity, at an antibody concentration of 10 nM. 8551
- antibodies exhibit apoptotic activity of less than 20% cytolysis ⁇ i.e. % cytotoxicity), or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytolysis (cytotoxicity), as measured in an in vitro or ex vivo cell killing assay.
- antibodies of the invention exhibit less than 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable apoptotic activity, at an antibody concentration of 10 nM.
- antibodies exhibit CDC activity of less than about 50% cytotoxicity, or less than cytotoxicity 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytotoxicity, as measured in an in vitro or ex vivo cell killing assay.
- antibodies of the invention exhibit less than 50%, 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable CDC activity, at an antibody concentration of 100 nM.
- antibodies exhibit ADCC activity of less than about 50% cytotoxicity, or less than cytotoxicity 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytotoxicity, as measured in an in vitro or ex vivo cell killing assay.
- antibodies of the invention exhibit less than 50%, 40%, 30%, 20%, 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable ADCC activity, at an antibody concentration of 100 nM.
- the present invention provides antibodies, antigen-binding proteins and Fc- fusion proteins that comprise recombinant polypeptides comprising a chimeric hinge, and further provide reduced effector functions.
- the properties of such recombinant polypeptides of the invention may be compared to the properties of one or more reference proteins. See the examples below for reference, or control antibodies and antigen-binding proteins which have corresponding variable regions and constant regions (e.g.
- a wild-type lgG1 C H region (SEQ ID NO: 13) or a wild-type lgG4 C H region (SEQ ID NO: 15)) compared to the chimeric antibodies of the invention, and may be used in certain testing methodologies for comparison of functional or pharmacokinetic properties to the antibodies and antigen-binding proteins of the invention. It is understood that a corresponding wild-type IgG C H region differs from chimeric C H regions of the invention in that the "wild-type" IgG C H region is derived from the natural IgG amino acid sequence containing (from N-terminal to C-terminal) a CH1 domain, a hinge, a CH2 domain, and a CH3 domain.
- Wild-type IgG may include variants having one or more amino acid modifications while retaining essentially the same functional characteristics as natural IgG.
- a corresponding antibody or polypeptide may be assembled to have the same target binding domain (e.g. V H and/or V L ) as the antibody or polypeptide having the chimeric CH region, or otherwise has essentially the same functionality for the purpose of comparison in certain assays.
- isolated antibodies of the invention bind weakly to FcyR expressing cells, e.g. effector cells, but however lack effector functions, such as cytotoxicity and proliferation, compared to the effector functions of a corresponding antibody comprising a wild-type lgG1 or lgG4 C H region.
- the invention provides a recombinant polypeptide comprising a chimeric hinge region.
- the chimeric hinge region comprises a human lgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering).
- the chimeric hinge region comprises: a human lgG1 or a human lgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering) and a human lgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering), from N-terminus to C-terminus.
- the chimeric hinge region comprises: an upper hinge amino acid sequence from positions 216 to 227 (EU numbering) selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:5, and a lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering), from N-terminus to C-terminus.
- the invention provides a recombinant polypeptide comprising, from N- terminus to C-terminus, a CH1 domain, a chimeric hinge, a CH2 domain, and a CH3 domain wherein:
- the CH1 domain comprises at least the amino acid sequence DKKV or DKRV from positions 212 to 215 (EU numbering)
- the chimeric hinge comprises a human lgG1 or a human lgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering) and a human lgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering)
- the CH2 domain comprises a human lgG4 CH2 domain amino acid sequence from positions 237 to 340 (EU numbering)
- the CH3 domain comprises a human lgG1 or a human lgG4 CH3 domain sequence from positions 341 to 447 (EU numbering), or a variant thereof.
- the present invention provides a monoclonal antibody comprising a heavy chain constant region comprising or consisting of SEQ NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, or SEQ ID NO: 31. In another embodiment, the present invention provides a monoclonal antibody comprising at least one heavy chain with a constant region comprising or consisting of SEQ ID NO: 38 or 37. 8551
- the recombinant polypeptide is selected from the group consisting of an antibody, antigen-binding protein and receptor-Fc fusion protein.
- the isolated antibody, antigen-binding protein, or receptor-Fc fusion protein comprises a heavy chain construct comprising a CH region, from N-terminus to C-terminus, a CH1 domain, a chimeric hinge, a CH2 domain, and a CH3 domain, wherein the CH1 domain comprises the amino acid sequence DKKV or DKRV, the chimeric hinge comprises a human lgG1 or a human lgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering), or a natural variant thereof, and a human lgG2 lower hinge amino acid sequence from positions 228 to 236 (EU numbering), the CH2 domain comprises a human lgG4 CH2 domain sequence from positions 237 to 340 (EU numbering), or a natural variant thereof, and the CH3 domain comprises a human lgG1 or a human lgG4 CH3 domain sequence from positions 341 to 447 (EU numbering), or a natural variant thereof, and the CH1 domain comprises the amino acid sequence
- the present invention provides an isolated antibody, antigen-binding protein, or receptor-Fc fusion protein comprising a heavy chain construct comprising a CH region, from N-terminus to C-terminus, a CH1 domain, a chimeric hinge, a 8551
- the CH1 domain comprises the amino acid sequence DKKV or DKRV
- the chimeric hinge comprises a human lgG1 or a human lgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering), or a natural variant thereof, and a human lgG2 lower hinge amino acid sequence from positions 228 to 236 (EU numbering)
- the CH2 domain comprises a human lgG4 CH2 domain sequence from positions 237 to 340 (EU numbering), or a natural variant thereof
- the CH3 domain comprises a human lgG1 or a human lgG4 CH3 domain sequence from positions 341 to 447 (EU numbering), or a natural variant thereof
- the CH region has an amino acid sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% identity to SEQ ID NO: 30 or SEQ ID NO: 31.
- the CH region has an amino acid sequence with at least about 95%, or about 96%, or about 97%,
- Such "variant" or “natural variant” C H domains of the invention comprise one or more additions, deletions, or substitutions of amino acids when compared to the wild-type sequence that such C H domains of the invention are derived from, but essentially function as desired.
- the C H domain or Fc domain exhibits weak or no binding to certain FcyR expressing cells, e.g. effector cells, resulting in altered effector functions, such as cytotoxicity and proliferation.
- such variants include modifications such as additions, deletions, or substitutions of amino acids in the CH3 domain engineered for the isolation of bispecific molecules.
- the present invention provides a monoclonal antibody comprising a heavy chain variable region and a heavy chain constant region comprising or consisting of SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37, or a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% to such heavy chain constant region.
- the present invention provides a monoclonal antibody comprising a light chain variable region, a heavy chain variable region and a heavy chain constant region comprising or consisting of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37, or a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% to such heavy chain constant region.
- the invention is an isolated antibody, or antigen- binding fragment thereof, comprising a heavy chain constant region (C H ) having (i) the amino acid sequence of SEQ NO: 1 or having the amino acid sequence encoded by SEQ ID NO: 33, or (ii) the amino acid sequence of SEQ NO: 31 or having the amino acid sequence 8551
- the invention is an isolated antibody, or antigen-binding fragment thereof, comprising a heavy chain constant region (C H ) having (i) the amino acid sequence of SEQ NO: 2 or having the amino acid sequence encoded by SEQ ID NO: 32, or (ii) the amino acid sequence of SEQ NO: 30 or having the amino acid sequence encoded by SEQ ID NO: 28, or (iii) a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% identity to a sequence described in (i) or (ii).
- C H heavy chain constant region
- the invention is an isolated antibody, or antigen- binding fragment thereof, comprising a heavy chain constant region (C H ) having (i) the amino acid sequence of SEQ NO: 38 or having the amino acid sequence encoded by SEQ ID NO: 36, or (ii) the amino acid sequence of SEQ NO: 37 or having the amino acid sequence encoded by SEQ ID NO: 35, or (iii) a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% identity to a sequence described in (i) or (ii).
- C H heavy chain constant region
- the isolated antibody is a monoclonal antibody. In other embodiments, the isolated antibody, or antigen binding fragment thereof, is a humanized, chimeric, single-chain antibody or bispecific antibody.
- the invention is an Fc-containing protein comprising (i) the amino acid sequence of SEQ NO: 1 or the amino acid sequence encoded by SEQ ID NO: 33, or (ii) the amino acid sequence of SEQ NO: 31 or the amino acid sequence encoded by SEQ ID NO: 29, or (iii) a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% identity to a sequence described in (i) or (ii).
- the invention is an Fc-containing protein comprising (i) the amino acid sequence of SEQ NO: 2 or the amino acid sequence encoded by SEQ ID NO: 32, or (ii) the amino acid sequence of SEQ NO: 30 or the amino acid sequence encoded by SEQ ID NO: 28, or (iii) a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% identity to a sequence described in (i) or (ii).
- the invention is an Fc-containing protein comprising (i) the amino acid sequence of SEQ NO: 38 or the amino acid sequence encoded by SEQ ID NO: 36, or (ii) the amino acid sequence of SEQ NO: 37 or the amino acid sequence encoded by SEQ ID NO: 35, or (iii) a sequence with at least about 95%, or about 96%, or about 97%, or about 98%, or about 99% identity to a sequence described in (i) or (ii).
- the present invention provides a composition comprising the antibody, antigen-binding protein or Fc fusion protein described. 8551
- the present invention provides an antibody or antigen-binding protein that lacks cytotoxic or cytolytic effector function.
- the antibody or antigen-binding protein lacks cytotoxic or cytolytic effector function and comprises SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37.
- the present invention provides an antibody or antigen-binding protein having cytotoxic activity that is at least 10-fold less, or at least 50-fold less, or at least 100-fold less, or at least 1000-fold less, or at least 10000-fold less than the cytotoxic activity of a corresponding antibody comprising a wild-type lgG1 or wild-type lgG4 CH region.
- the present invention provides an antibody capable of binding to an FcyR, wherein such antibody comprises a recombinant polypeptide comprising SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37.
- the antibody is capable of binding to an FcyR with lower affinity compared to the binding affinity of a corresponding antibody comprising a wild-type lgG1 or wild-type lgG4 heavy chain constant region.
- the antibody is capable of activating an FcyR at a half-maximal concentration (EC 50 ) of greater than about 10 nM, or about 20 nM, or about 30 nM, or about 40 nM, about 50 nM, about 100 nM.
- the FcyR is a human or cynomolgus FcyRII.
- the FcyR is FcyRIIA or FcyRIIB.
- the antibody is capable of binding to FcyRIIA having an affinity (K D value) of about 10 ⁇ , or about 20 ⁇ , or about 30 ⁇ , or about 40 ⁇ , about 50 ⁇ , about 100 ⁇ .
- the antibody or recombinant polypeptide binds to FcyRIIA with an affinity greater than the affinity of the antibody or recombinant polypeptide to FcyRIIB.
- the antibody is capable of binding to FcyRIIB having an affinity (KD value) of about 10 ⁇ , or about 20 ⁇ , or about 30 ⁇ , or about 40 ⁇ , about 50 ⁇ , about 100 ⁇ .
- affinity KD value
- the antibody or recombinant polypeptide binds to FcyRIIA with an affinity (K D value) substantially similar to the affinity of the antibody or recombinant polypeptide to FCYRI IB.
- the chimeric antibodies of the invention may engage, and even indirectly enhance FcYRIIA-mediated activity, even though the chimeric antibodies may have wild-type affinities for FCYRI IA.
- certain antibodies, and thus therapeutics may benefit from a weakened interaction (compared to wild-type antibodies) with the inhibitory receptor FcyRIIB, which may shift the balance between the activating FcyRIIA and the inhibitory FcyRIIB receptors in favor of activation.
- the present invention encompasses the production of monoclonal antibodies comprising a recombinant polypeptide comprising SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37 and having specificities for various target antigens.
- the invention provides a method for producing an antibody comprising: a) introducing the vector comprising a nucleic acid molecule encoding an antibody, or fragment thereof, of the invention into a mammalian host cell, b) culturing the host cell capable of expressing the antibody, and c) isolating the antibody from the cell culture media.
- Monoclonal antibodies of the present invention may e.g. be produced by the hybridoma method first described by Kohler et al., Nature 256, 495 (1975), or may be produced by recombinant DNA methods. Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in, for example, Clackson et al., Nature 352, 624-628 (1991 ) and Marks et al., J. Mol. Biol. 222, 581-597 (1991 ). Monoclonal antibodies may be obtained from any suitable source.
- monoclonal antibodies may be obtained from hybridomas prepared from murine splenic B lymphocyte cells obtained from mice immunized with an antigen of interest, for instance, in the form of cells expressing the antigen on the surface, or a nucleic acid encoding an antigen of interest.
- Monoclonal antibodies may also be obtained from hybridomas derived from antibody- expressing cells of immunized humans or non-human mammals such as rats, rabbits, dogs, primates, etc.
- the antibody of the invention is a human antibody.
- Human monoclonal antibodies may be generated using transgenic or transchromosomal mice carrying parts of the human immune system rather than the mouse system.
- transgenic and transchromosomic mice include mice referred to herein as VELOCIMMUNE mice, HuMAb mice and KM mice, respectively, and are collectively referred to herein as "transgenic mice” and are described hereinabove.
- Splenocytes from these transgenic mice may be used to generate hybridomas that secrete human monoclonal antibodies according to well-known techniques.
- Human monoclonal or polyclonal antibodies of the present invention, or antibodies of the present invention originating from other species may also be generated transgenically through the generation of another non-human mammal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom.
- antibodies may be produced in, and recovered from, the milk of goats, cows, or other mammals. See for instance US 5,827,690, US 5,756,687, US 5,750,172 and US 5,741 ,957. 8551
- Expression vectors comprising a mouse UP-II promoter operatively linked to the DNA encoding the Ig heavy and light chain sequences of interest may be engineered for expression and secretion of the proteins of interest in urine of a transgenic animal (See, e.g., US 5,824,543).
- human antibodies of the present invention or antibodies of the present invention from other species may be generated through display-type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules may be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art (see for instance Hoogenboom et al., J. Mol. Biol.
- the engineered heavy chain constant (C H ) regions of the invention will provide reduced effector functions.
- the present invention provides the antibodies of the invention produced by a host cell.
- the invention provides a method for producing a monoclonal antibody comprising a) immunizing VELOCIMMUNE® mice with an antigen sufficient to cause an antibody immune response, b) obtaining serum from such mice and testing for antibody titer against said antigen, c) harvesting B cells from the spleens of such immunized mice shown to have elevated antibody titers and fusing said B cells with mouse myeloma cells to form such hybridoma, d) isolating chimeric antibody from such hybridoma by protein A chromatography, such chimeric antibody having a human variable region and a mouse constant region, e) selecting a chimeric antibody having desirable characteristics, and f) replacing the mouse constant regions of such antibodies with a human constant region of the invention, for example, such human constant region comprising SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO:
- the antibody of the invention is a full-length IgG antibody. In another embodiment, the antibody of the invention is an antibody fragment or a single- 8551
- the antibody of the invention is a fully human IgG antibody.
- the antibody is a bispecific antibody wherein each antigen-binding domain of such molecule or antibody comprises a V H region paired with a V
- the bispecific antibody comprises a first antigen- binding domain and a second antigen binding domain each comprise different, distinct V H regions ith a common V L region.
- the bispecific antibodies are constructed comprising a first antigen-binding domain that specifically binds a first antigen, wherein the first antigen-binding domain comprises an V H region / V L region pair derived from a first antibody directed against the first antigen; and a second antigen-binding domain that specifically binds a second antigen, wherein the second antigen-binding domain comprises an V H region derived from a second antibody directed against a second antigen paired with an V L region derived from the first antibody (e.g., the same V L region that is included in the antigen-binding domain of the first antibody).
- the heavy chain of at least one of the antibodies i.e.
- the first antibody or the second antibody or both antibodies, in a bispecific antibody is modified to comprise a chimeric heavy chain constant region (C H region).
- the bispecific antibody comprises SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37.
- two antibodies of different specificity use the same light chain.
- the heavy chain of at least one of the Ig heavy chains in a bispecific antibody is modified to comprise a chimeric heavy chain constant region comprising a recombinant polypeptide of the invention.
- at least one of the heavy chains is modified in the CH3 domain resulting in a differential affinity for the bispecific antibody for an affinity reagent, such as Protein A, for ease of isolation.
- At least one of the heavy chains in such bispecific antibody comprises an amino acid modification at i) 95R or ii) 95R and 96F in the IMGT numbering system (95R and 96F correspond to 435R and 436F in the EU numbering system).
- the antibody is a bispecific antibody wherein the bispecific antibody comprises:
- the heavy chain of (a) or (b) or both (a) and (b) further comprises the heavy chain constant region comprising SEQ ID NO: 1 or SEQ ID NO: 31 .
- the antibody is a bispecific antibody wherein the bispecific antibody comprises:
- the heavy chain of (a) or (b) or both (a) and (b) further comprises the heavy chain constant region comprising SEQ ID NO:2 or SEQ ID NO: 30.
- At least one of the heavy chains of (a) or (b) in such bispecific antibody hereinabove comprises an amino acid modification at (i) 435R or (ii) 435R and 436F (EU numbering) ((i)95R or (ii) 95R and 96F in the IMGT numbering system).
- the antibody is a bispecific antibody wherein the bispecific antibody comprises (a) a first heavy chain comprising an antigen-binding domain capable of recognizing and binding to a first target antigen, and a first heavy chain constant region comprising SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO: 30, or SEQ ID NO: 31 ; (b) a second heavy chain comprising an antigen-binding domain capable of recognizing and binding to a second target antigen, and a second heavy chain constant region comprising SEQ ID NO: 38 or SEQ ID NO: 37; and (c) common light chain antigen-binding domain capable of recognizing and binding to the first or second target antigen.
- the antibody is a monovalent antibody. Accordingly, in one embodiment, the antibody is a monovalent antibody, wherein said antibody is constructed by a method comprising : i) providing a nucleic acid molecule encoding the light chain of said monovalent antibody, said construct comprising a nucleotide sequence encoding the V L region of a selected antigen specific antibody and a nucleotide sequence encoding the constant CL region of an Ig, wherein said nucleotide sequence encoding the V L region of a selected antigen specific antibody and said nucleotide sequence encoding the C L region of an Ig are operably linked together, and wherein the nucleotide sequence encoding the CL region has been modified such that the CL region does not contain any amino acids capable of forming disulfide bonds or covalent bonds with other peptides comprising an 8551
- nucleic acid construct encoding the heavy chain of said monovalent antibody, said construct comprising a nucleotide sequence encoding the V H region of a selected antigen specific antibody and a nucleotide sequence encoding a constant C H region of a human Ig, wherein the nucleotide sequence encoding the C H region comprises nucleic acids encoding SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37, wherein such nucleotide sequence has been modified and does not comprise any amino acid residues which participate in the formation of disulphide bonds or covalent or stable non- covalent inter-heavy chain bonds with other peptides comprising an identical amino acid sequence of the C H region of the human Ig in the presence of polyclonal human Ig
- the antibody is a monovalent antibody, which comprises: i) a variable region or an antigen-binding domain of said region, and ii) a C H region of an immunoglobulin or a fragment thereof comprising SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 38, or SEQ ID NO: 37, wherein the C H region or fragment thereof has been modified such that the region does not comprise any amino acid residues which are capable of forming disulfide bonds with an identical C H region or other covalent or stable non-covalent inter-heavy chain bonds with an identical C H region in the presence of polyclonal human IgG.
- sequence of said monovalent antibody has been modified so that it does not comprise any acceptor sites for N-linked glycosylation.
- antibodies described herein may be modified by inclusion of any suitable number of such modified amino acids and/or associations with conjugated substituents. Suitability in this context is generally determined by the ability to at least substantially retain the antibody or antigen binding fragment's selectivity and/or specificity associated.
- the modified amino acid may, for instance, be selected from a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, an amino acid conjugated to a lipid moiety, or an amino acid conjugated to an organic derivatizing agent.
- Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production (e.g., N-linked glycosylation at N-X-S/T motifs during expression in mammalian cells) or modified by synthetic means.
- Non-limiting examples of a modified amino acid include a glycosylated amino acid, a sulfated amino acid, a prenylated (e.
- Antibodies of the invention may also be chemically modified by covalent conjugation to a polymer to, for instance, further increase their circulating half-life.
- Exemplary polymers, and methods to attach them to peptides are illustrated in for instance US 4,766,106, US 4,179,337, US 4,495,285 and US 4,609,546.
- Additional illustrative polymers include polyoxyethylated polyols and polyethylene glycol (PEG) (e.g., a PEG with a molecular weight of between about 1 ,000 and about 40,000, such as between about 2,000 and about 20,000, e.g., about 3,000-12,000 g/mol).
- PEG polyethylene glycol
- antibodies comprising one or more radiolabeled amino acids are provided.
- a radiolabeled antibody may be used for both diagnostic and therapeutic purposes.
- antibodies of the present invention may be conjugated to a molecule which is a therapeutic agent or a detectable marker.
- the therapeutic agent is a cytotoxic agent, such as a radioisotope.
- radioisotopes for polypeptides include, but are not limited to, 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, and 125 l, 131 1, 186 Re, and 225 Ac.
- a radioisotope may be conjugated by a chloramine T method.
- a detectable marker may be a radiolabel, an enzyme, a chromophore, or a fluorescent label.
- the invention relates to an expression vector encoding a polypeptide, e.g. an antibody, antigen-binding protein or receptor-Fc fusion protein of the invention.
- a polypeptide e.g. an antibody, antigen-binding protein or receptor-Fc fusion protein of the invention.
- Such expression vectors may be used for recombinant production of polypeptides of the invention.
- An expression vector in the context of the present invention may be any suitable vector, including chromosomal, non-chromosomal, and synthetic nucleic acid vectors (a nucleic acid sequence comprising a suitable set of expression control elements).
- suitable vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral nucleic acid (RNA or DNA) vectors.
- an antibody-encoding nucleic acid molecule is comprised in a naked DNA or RNA vector, including, for example, a linear expression element (as described in, for instance, Sykes and Johnston, Nat Biotech 12, 355-59 (1997)), a compacted nucleic acid vector (as described in for instance US 6,077,835 and/or WO 00/70087), or a plasmid vector such as pBR322, pUC 19/18, or pUC 118/1 19.
- a linear expression element as described in, for instance, Sykes and Johnston, Nat Biotech 12, 355-59 (1997)
- a compacted nucleic acid vector as described in for instance US 6,077,835 and/or WO 00/70087
- a plasmid vector such as pBR322, pUC 19/18, or pUC 118/1 19.
- Such nucleic acid vectors and the usage thereof are well known in the art (see, for instance, US 5,589,466 and US 5,97
- the vector comprises the nucleic acid molecule encoding an antibody or polypeptide of the invention, including an expression vector comprising the nucleic acid molecules described wherein the nucleic acid molecule is operatively linked to an expression control sequence.
- the vector is suitable for expression of a polypeptide or antibody of the invention in a bacterial cell.
- expression vectors include expression vectors such as BlueScript (Stratagene), pIN vectors (Van Heeke & Schuster, J Biol Chem 264, 5503-5509 (1989), pET vectors (Novagen, Madison, Wl) and the like).
- An expression vector may also or alternatively be a vector suitable for expression in a yeast system. Any vector suitable for expression in a yeast system may be employed. Suitable vectors include, for example, vectors comprising constitutive or inducible promoters such as yeast alpha factor, alcohol oxidase and PGH (reviewed in: F. Ausubel et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York (1987), and Grant et al., Methods in EnzymoH 53, 516-544 (1987)).
- constitutive or inducible promoters such as yeast alpha factor, alcohol oxidase and PGH
- a vector comprising a nucleic acid molecule of the invention is provided, wherein the nucleic acid molecule is operatively linked to an expression control sequence suitable for expression in a mammalian host cell.
- Expression control sequences are engineered to control and drive the transcription of genes of interest, and subsequent expression of proteins in various cell systems.
- Plasmids combine an expressible gene of interest with expression control sequences (i.e. expression cassettes) that comprise desirable elements such as, for example, promoters, enhancers, selectable markers, operators, etc.
- expression control sequences i.e. expression cassettes
- desirable elements such as, for example, promoters, enhancers, selectable markers, operators, etc.
- antibody-encoding nucleic acid molecules may comprise or be associated 8551
- any suitable promoter, enhancer, selectable marker, operator, repressor protein, polyA termination sequences and other expression-facilitating elements are any suitable promoter, enhancer, selectable marker, operator, repressor protein, polyA termination sequences and other expression-facilitating elements.
- Promoter indicates a DNA sequence sufficient to direct transcription of a DNA sequence to which it is operably linked, i.e., linked in such a way as to permit transcription of the antibody-encoding nucleotide sequence when the appropriate signals are present.
- the expression of a antibody-encoding nucleotide sequence may be placed under control of any promoter or enhancer element known in the art. Examples of such elements include strong expression promoters (e.
- CMV-MIE CMV major IE
- the vector comprises a promoter selected from the group consisting of SV40, CMV, CMV-IE, CMV-MIE, RSV, SL3-3, MMTV, Ubi, UbC and HIV LTR.
- Nucleic acid molecules of the invention may also be operatively linked to an effective poly (A) termination sequence, an origin of replication for plasmid product in E. coli, an antibiotic resistance gene as selectable marker, and/or a convenient cloning site (e.g., a polylinker).
- Nucleic acids may also comprise a regulatable inducible promoter (inducible, repressable, developmentally regulated) as opposed to a constitutive promoter such as CMV IE (the skilled artisan will recognize that such terms are actually descriptors of a degree of gene expression under certain conditions).
- Selectable markers are elements well-known in the art. Under the selective conditions, only cells that express the appropriate selectable marker can survive. Commonly, selectable marker genes express proteins, usually enzymes, that confer resistance to various antibiotics in cell culture. In other selective conditions, cells that express a flourescent protein marker are made visible, and are thus selectable.
- Embodiments include beta-lactamase (bla) (beta- lactam antibiotic resistance or ampicillin resistance gene or ampR), bis (blasticidin resistance acetyl transferase gene), bsd (blasticidin-S deaminase resistance gene), bsr (blasticidin-S resistance gene), Sh ble (Zeocin® resistance gene), hygromycin phosphotransferase (hpt) (hygromycin resistance gene), tetM (tetracycline resistance gene or tetR), neomycin phosphotransferase II (npt) (neomycin resistance gene or neoR), kanR (kanamycin resistance gene), and pac (puromycin resistance gene).
- bla beta-lactamase
- ampR ampicillin resistance gene
- bis blasticidin resistance acetyl transferase gene
- bsd blasticidin-S deaminase resistance gene
- bsr blastici
- the vector comprises one or more selectable marker genes selected from the group consisting of bla, bis, BSD, bsr, Sh ble, hpt, tetR, tetM, npt, kanR and pac.
- the vector comprises one or more selectable marker genes encoding green fluorescent protein (GFP), enhanced green fluorescent protein 8551
- eGFP cyano fluorescent protein
- eCFP enhanced cyano fluorescent protein
- YFP yellow fluorescent protein
- gene expression in eukaryotic cells may be tightly regulated using a strong promoter that is controlled by an operator that is in turn regulated by a regulatory fusion protein (RFP).
- the RFP consists essentially of a transcription blocking domain, and a ligand-binding domain that regulates its activity. Examples of such expression systems are described in US20090162901 A1 , which is herein incorporated by reference in its entirety.
- operator indicates a DNA sequence that is introduced in or near a gene in such a way that the gene may be regulated by the binding of the RFP to the operator and, as a result, prevents or allow transcription of the gene of interest, i.e. a nucleotide encoding a polypeptide of the invention.
- a number of operators in prokaryotic cells and bacteriophage have been well characterized (Neidhardt, ed. Escherichia coli and Salmonella; Cellular and Molecular Biology 2d. Vol 2 ASM Press, Washington D.C. 1996). These include, but are not limited to, the operator region of the LexA gene of E.
- the transcription blocking domain of the RFP is a restriction enzyme, such as NotI
- the operator is the recognition sequence for that enzyme.
- the operator must be located adjacent to, or 3' to the promoter such that it is capable of controlling transcription by the promoter. For example, U.S. Pat. No.
- tetO sequences be within a specific distance from the TATA box.
- the operator is preferably placed immediately downstream of the promoter. In other embodiments, the operator is placed within 10 base pairs of the promoter.
- the operator is selected from the group consisting of tet operator (tetO), NotI recognition sequence, LexA operator, lactose operator, tryptophan operator and Arc operator (AO).
- the repressor protein is selected from the group consisting of TetR, LexA, Lacl, TrpR, Arc, LambdaCI and GAL4.
- the transcription blocking domain is derived from a eukaryotic repressor protein, e.g. a repressor domain derived from GAL4.
- cells are engineered to express the tetracycline repressor protein (TetR) and a protein of interest is placed under transcriptional 8551
- TetR tetracycline repressor protein
- TetR Two tandem TetR operators (tetO) are placed immediately downstream of a CMV-MIE promoter/enhancer in the vector. Transcription of the gene encoding the protein of interest directed by the CMV-MIE promoter in such vector may be blocked by TetR in the absence of tetracycline or some other suitable inducer (e.g. doxycycline). In the presence of an inducer, TetR protein is incapable of binding tetO, hence transcription then translation (expression) of the protein of interest occurs. (See, e.g., US Patent No. 7,435,553, which is herein incorporated by reference in its entirety.)
- Another exemplary cell expression system includes regulatory fusion proteins such as TetR-ER L BDT2 fusion protein, in which the transcription blocking domain of the fusion protein is TetR and the ligand-binding domain is the estrogen receptor ligand-binding domain (ER L BD) with T2 mutations (ER L BDT2; Feil et al. (1997) Biochem. Biophys. Res. Commun. 237:752-757).
- ER L BD estrogen receptor ligand-binding domain
- fusion protein Arc2-ER L BoT2 a fusion protein consisting of a single chain dimer consisting of two Arc proteins connected by a 15 amino acid linker and the ER L BDT2 (supra), involves an Arc operator (AO), more specifically two tandem arc operators immediately downstream of the CMV-MIE promoter/enhancer.
- Cell lines may be regulated by Arc2-ER L BDT2, wherein cells expressing the protein of interest are driven by a CMV-MIE/Arc02 promoter and are inducible with the removal of tamoxifen. (See, e.g., US 20090162901 A1 , which is herein incorporated by reference.)
- a vector of the invention comprises a CMV-MIE/TetO or CMV-MIE/A02 hybrid promoter.
- the vectors of the invention may also employ Cre-/ox tools for recombination technology in order to facilitate the replication of a gene of interest.
- a Cre-/ox strategy requires at least two components: 1 ) Cre recombinase, an enzyme that catalyzes recombination between two loxP sites; and 2) loxP sites (e.g. a specific 34-base pair bp sequence consisting of an 8-bp core sequence, where recombination takes place, and two flanking 13-bp inverted repeats) or mutant lox sites.
- Cre recombinase an enzyme that catalyzes recombination between two loxP sites
- loxP sites e.g. a specific 34-base pair bp sequence consisting of an 8-bp core sequence, where recombination takes place, and two flanking 13-bp inverted repeats
- yeast-derived FLP recombinase may be utilized with the consensus sequence FRT (see also, e.g. Dymecki, S. PNAS 93(12): 6191 -6196).
- a gene i.e. a nucleotide sequence encoding a 8551
- recombinant polypeptide of the invention is inserted within an expression-enhancing sequence of the expression cassette, and is optionally operably linked to a promoter, wherein the promoter-linked gene is flanked 5' by a first recombinase recognition site and 3' by a second recombinase recognition site.
- a promoter-linked gene is flanked 5' by a first recombinase recognition site and 3' by a second recombinase recognition site.
- a second promoter-linked gene is downstream (3') of the first gene and is flanked 3' by the second recombinase recognition site.
- a second promoter-linked gene is flanked 5' by the second recombinase site, and flanked 3' by a third recombinase recognition site.
- the recombinase recognition sites are selected from a loxP site, a /ox51 1 site, a /ox2272 site, and a FRT site.
- the recombinase recognition sites are different.
- the host cell comprises a gene capable of expressing a Cre recombinase.
- the vector comprises a first gene encoding a light chain of an antibody or a heavy chain of an antibody of the invention, and a second gene encoding a light chain of an antibody or a heavy chain of an antibody of the invention.
- the vector further comprises an X-box-binding-protein 1 (mXBP1 ) gene capable of enhancing protein production/protein secretion through control of the expression of genes involved in protein folding in the endoplasmic reticulum (ER).
- mXBP1 X-box-binding-protein 1
- cell includes any cell that is suitable for expressing a recombinant nucleic acid sequence.
- Cells include those of prokaryotes and eukaryotes (single-cell or multiple-cell), bacterial cells (e.g., strains of E. coli, Bacillus spp., Streptomyces spp., etc.), mycobacteria cells, fungal cells, yeast cells (e.g. S. cerevisiae, S. pombe, P. partoris, P. methanol ica, etc.), plant cells, insect cells (e.g.
- the cell is a human, monkey, ape, hamster, rat or mouse cell.
- the cell is eukaryotic and is selected form the following cells: CHO (e.g. CHO K1 , DXB-1 1 CHO, Veggie-CHO), COS (e.g. COS- 7), retinal cells, Vera, CV1 , kidney (e.g.
- the cell comprises one or more viral genes, e.g. a retinal cell that expresses a viral gene (e.g. a PER.C6® cell).
- a viral gene e.g. a PER.C6® cell.
- the invention relates to a recombinant eukaryotic or prokaryotic host cell, such as a transfectoma, which produces an antibody of the invention 8551
- the present invention provides a cell comprising a nucleic acid stably integrated into the cellular genome that comprises a sequence coding for expression of an antibody comprising a recombinant polypeptide of the present invention.
- the present invention provides a cell comprising a non-integrated (i.e., episomal) nucleic acid, such as a plasmid, cosmid, phagemid, or linear expression element, which comprises a sequence coding for expression of an antibody comprising the recombinant polypeptide of the invention.
- the present invention provides a cell line produced by stably transfecting a host cell with a plasmid comprising an expression vector of the invention.
- the invention relates to a method for producing an antibody, or antigen-binding protein, or receptor-Fc fusion protein of the invention, said method comprising the steps of a) culturing a hybridoma or a host cell of the invention as described herein above, and b) purifying the antibody, or antigen-binding protein, or receptor-Fc fusion (supra) from the culture media.
- the invention relates to a composition
- a composition comprising: an antibody or antigen-binding fragment thereof, antigen-binding protein or receptor-Fc fusion protein as defined herein, or a bispecific molecule as defined herein.
- compositions may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
- the pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients should be suitable for the chosen antibody of the present invention and the chosen mode of administration.
- the actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the appropriate stability of drug substance, desired therapeutic response for a particular patient, composition, and mode of administration.
- the selected dosage level will depend upon a variety of pharmacokinetic factors.
- the pharmaceutical composition may be administered by any suitable route and mode. Suitable routes of administering an antibody of the present invention in vivo are well known in the art and may be selected by those of ordinary skill in the art. (Daugherty, AL, and Msrny, RJ, Adv Drug Delivery Rev, 58(5-6): 686-706 (2006)). 8551
- Labeled antibodies of the invention can be used for diagnostic purposes to detect, diagnose, or monitor diseases or disorders.
- the invention provides for the detection or diagnosis of a disease or disorder, comprising: (a) assaying the existence of antigen in cells or tissue samples of a subject using one or more antibodies that immunospecifically bind to the target antigen; and (b) comparing the level of the antigen with a control level, e.g. levels in normal tissue samples, whereby an increase in the assayed level of antigen compared to the control level of antigen is indicative of the disease or disorder, or indicative of the severity of the disease or disorder.
- a control level e.g. levels in normal tissue samples
- Antibodies of the invention can be used to assay antigen levels in a biological sample using immunohistochemical methods well-known in the art.
- Other antibody-based methods useful for detecting protein include immunoassays such as the enzyme linked immunoassay (ELISA) and the radioimmunoassay (RIA).
- ELISA enzyme linked immunoassay
- RIA radioimmunoassay
- Suitable antibody labels may be used in such kits and methods, and labels known in the art include enzyme labels, such as alkaline phophatase and glucose oxidase; radioisotope labels, such as iodine ( 125 l, 131 1), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 121 ln), and technetium ( 99m Tc); and luminescent labels, such as luminol and luciferase; and flourescent labels, such as flourescein and rhodamine.
- enzyme labels such as alkaline phophatase and glucose oxidase
- radioisotope labels such as iodine ( 125 l, 131 1), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 121 ln), and technetium ( 99m Tc)
- luminescent labels such as luminol and luciferase
- flourescent labels such as flourescein
- Presence of labeled antibodies may be detected in vivo for diagnosis purposes.
- diagnosis comprises: a) administering to a subject an effective amount of a labeled antibody; b) waiting for a time interval following administration for permitting labeled antibody to concentrate at sites where antigen may be detected and to allow for unbound labeled antibody to be cleared to background level; c) determining a background level; and d) detecting the labeled antibody in the subject, such that detection of labeled antibody above the background level is indicative that the subject has the disease or disorder, or is indicative of the severity of the disease or disorder.
- the antibody is labeled with an imaging moiety suitable for detection using a particular imaging system known to those skilled in the art.
- Imaging may be determined by various methods known in the art, including comparing the amount of labeled antibody detected to a standard value previously determined for a particular imaging system.
- Methods and systems that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as positron emission tomography (PET), magnetic resonance imaging (MRI), and sonography.
- CT computed tomography
- PET positron emission tomography
- MRI magnetic resonance imaging
- sonography sonography
- Example 1 Preparation of the recombinant polypeptides
- Generating the recombinant polypeptides for example a chimeric C H lgG4 (SEQ ID NO: 31 ) and a chimeric CH lgG1 (SEQ ID NO: 30), was done using standard cloning techniques.
- the chimeric lgG4 C H was generated through a two-step PCR amplification process. Two PCR fragments, Fragment 1 and 2, were amplified using starting construct pR85501 (containing a wild-type hlgG4 C H DNA) and using primers oSP030-oSP031 and oSP032- oSP033 (see Table 8), respectively.
- the primers introduced the desired lgG2 lower hinge sequence (which encodes SEQ ID NO:3) and the flanking restriction sites into the fragments. These two fragments were then joined using PCR primers oSP031 and oSP033. The resulting sequence was inserted into pR85501via Xho1-Not1 restriction sites generating a vector construct pR85502 that contains a chimeric lgG4 C H having an lgG2 lower hinge sequence. The sequence was confirmed using primers KO_ol_RC120 and oKO021.
- Fragment 1 a was generated using primers oSP031 and oSP035 (see Table 8 below) from template pR85503 (which contains a wild-type human lgG1 C H DNA).
- Fragment 2a was amplified with primers oSP036 and oSP038 using pR85502 (containing the chimeric lgG4 C H DNA) as a template.
- Fragment 3 was made using primers oSP037 and oSP039 from template pR85503 (wild-type hlgG1 C H DNA).
- Fragments 1 a and 2a were joined using primers oSP031 and oSP038, which generated Fragment 4. Joining Fragments 2a and 3 using primers oSP036 and oSP039 created Fragment 5. Fragment 4 and 5 were then fused using primers oSP031 and oSP039. The resulting sequence was inserted into pR85501 via Xho1-Not1 restriction sites generating a construct pR85504 that has an lgG1 constant region with the lgG2 lower hinge and lgG4 CH2 domain. The sequence was confirmed using primers KO_oLRC120 and oKO021.
- OSP031 5'-AAGCTTATACTCGAGCTCTAGATTGGGAACCCGGGTCTCT-3' (SEQ ID NO: 17)
- OSP032 5'-CCCACCGTGCCCAGCACCACCTGTGGCAGGACCATCAGTCTTCCTGTTCCCCCCAAAA-3'
- OSP033 5'-TGTGTCTTCAGGGAGAGGGACAGAGACCCATTTACTCGCC GGCG-3' (antisense)
- OSP036 5'-AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCACCTGTG-3'
- KO_Fc-4-3 b'-GACCTCAGGGGTCCGGGAGATCAT-3' (SEQ ID NO: 26)
- Anti-hCD3 antibody (anti-hCD3 antibody "L2K”) was used to construct the chimeric antibodies of this example. L2K was obtained by well-known methods based on WO2004/106380.
- Anti-hCD3_L2K designated herein as Control Antibody 1 , contains a wild-type human lgG1 heavy chain constant region (SEQ ID NO: 13).
- bispecific antibodies created in accordance with the present Example comprise two separate antigen-binding domains (i.e., binding arms).
- An anti-hCD3 x anti- hCD20 (Bispecific antibody), designated herein as Control Antibody 2, was obtained as described in US Patent Application Publication No. US20100331527A1.
- the bispecific 8551 was obtained as described in US Patent Application Publication No. US20100331527A1.
- Control Antibody 2 contains wild-type human lgG4 heavy chain constant regions (SEQ ID NO:15), yet the anti-CD3 arm has a modified CH3 domain (SEQ ID NO:42) for ease of purification.
- Control Antibody 3 was obtained using the same methodologies as described herein to combine the variable regions of Control Ab 2 (Anti-hCD3 x anti-hCD20 Bispecific Ab) with a wild-type human lgG1 heavy chain constant regions (SEQ ID NO:13), having a modified CH3 domain (SEQ ID NO:41 ) in the anti-CD3 heavy chain arm.
- Control Antibody 4 contains an antigen-binding domain capable of binding CA9 antigen and a wild-type human lgG1 heavy chain constant region (SEQ ID NO: 13).
- Control Antibody 5 is an anti-hCD3 x anti-hCD20 bispecific antibody obtained according to the methods of PCT International Application No. PCT/US13/6051 1 , filed on September 19, 2013, which is herein incorporated by reference in its entirety. Briefly, a first antigen-binding domain comprising a heavy chain variable region derived from an anti-CD20 antibody ("CD20-VH”) is paired with a light chain variable region derived from an anti-CD3 antibody (“CD3-VL"). The CD20-VH/CD3-VL pairing creates an antigen-binding domain that specifically recognizes CD20.
- a second antigen-binding domain comprising a heavy chain variable region derived from an anti-CD3 antibody (“CD3-VH”) is paired with a light chain variable region derived from an anti-CD3 antibody (“CD3-VL”).
- CD3-VH/CD3-VL pairing creates an antigen-binding domain that specifically recognizes CD3.
- Control Antibody 5 is engineered with wild-type human lgG1 heavy chain constant regions (SEQ ID NO: 13), yet the anti-CD3 arm has a modified CH3 domain (SEQ ID NO:41 ) in the heavy chain constant region for ease of purification.
- Wild-type lgG1 Isotype Control contains the wt heavy chain constant region amino acid sequence of SEQ ID NO: 13.
- Wild- type lgG4 "CPPC" Isotype Control has the wt CH amino acid sequence of SEQ ID NO: 15, except having the "CPPC" hinge mutation S228P (according to EU numbering).
- Control Antibody 1 was replaced with a chimeric human constant region of the invention, e.g SEQ ID NO: 31 or SEQ ID NO: 30. Replacement of the constant region was done by obtaining a L2K variable region nucleic acid sequence (plasmid pR85505) that was amplified using primers oKO014 and oKO015 (see Table 8). 8551
- the L2K variable region (SEQ ID NO: 34) was then introduced into plasmid pR85502 using Sap1 restriction site for cloning.
- the sequence of the resulting plasmid pR85506 was confirmed using primers KO_ol_RC120 and oKO_Fc_4-3.
- This construct was used to generate Antibody 1 of the invention, slgG4-anti-CD3_L2K (also known herein as slgG4) (which comprises SEQ ID NO:31 ), using standard methodologies for isolating antibodies.
- the L2K variable region was amplified using primers oKO014 and oKO015 (see Table 8) using plasmid pR85505 as template. The variable region was then introduced into plasmid pR85504 using Sap1 restriction site for cloning. The sequence of the resulting plasmid pR85507 was confirmed using primers KO_ol_RC120 and oKO_Fc_4-3. This construct was used to generate Antibody 2 of the invention, slgG1-anti- CD3_L2K (also known herein as slgG1 ) (which comprises SEQ ID NO:30), using standard methodologies.
- Antibody 3 was constructed from the anti-CD3 x anti-CD20 bispecific antibody of Control Antibody (Ab) 5.
- Control Ab 5 had its heavy chain constant regions replaced with chimeric constant heavy chain regions, the anti-CD20 arm having an heavy chain constant region amino acid sequence comprising SEQ ID NO: 30, and the anti-CD3 arm having a mutation in the CH3 domain of the CH (SEQ ID NO:37) to create Antibody 3 (also known herein as slgGT).
- Antibody 4 was created from bispecific antibody Control Ab 5 whereas heavy chain constant regions were replaced with chimeric CH, the anti-CD20 arm having an heavy chain constant region amino acid sequence comprising SEQ ID NO: 31 , and the anti-CD3 arm having a mutation in the CH3 domain of the CH (SEQ ID NO:38) to create Antibody 4 (also known herein as slgG4 * ).
- chimeric antibodies comprising constant regions of SEQ ID NO:30 or SEQ ID NO:31 (or bispecific antibodies comprising SEQ ID NO:30/37 or SEQ ID NO:31/38), and the control antibodies, were used in certain experiments set out in the Examples that follow.
- Example 3 Chimeric Antibodies Specifically Bind to Jurkat cells
- FACS fluorescence-activated cell sorting
- U937 cells a monocyte cell line expressing FcyRI and FcyRIIA, were plated and allowed to incubate with serial dilutions of Ab (the highest concentration of Ab used is 50nM). Cells were incubated with Abs for 1 hr at 4°C then washed twice. U937 cells were then incubated with secondary Ab (FITC goat anti-human Fab) for 30 min at 4°C then washed twice. Cells were analyzed by flow cytometry using standard methods and median fluorescent intensity (MFI) was recorded. Results are summarized in Table 9 and Figure 7 where it is demonstrated that chimeric Abs, Antibody 1 (slgG4) and Antibody 2 (slgG1 ), bind to U937 cells at high concentrations.
- MFI median fluorescent intensity
- U937 cells were used as a positive killer effector control in the following cytoassay. As such, the ability of antibodies with chimeric C H regions to kill U937 cells via Fc/FcyR interactions was tested. Calcein killing assays were carried out using the following protocol: Human and cynomolgus Peripheral Blood Mononuclear Cells (PBMCs) were isolated over Ficoll-Paque (GE Healthcare Life Sciences) or via Lympholyte-Mammal density cell separation media (Cedarlane Laboratories), respectively.
- PBMCs Peripheral Blood Mononuclear Cells
- the isolated PBMCs were activated over a course of several days with media containing recombinant human IL-2 (30U/ml) and T-cell activation beads (anti-CD3/CD28 for human PBMC, anti-CD2/CD3/CD28 for cynomolgus PBMC).
- Activated T-cells were isolated from the PBMCs by centrifugation, then resuspended in 1 ml media. The magnetized beads were removed from the T-cells.
- Target cells (U937) were labeled with calcein, then washed and followed by incubation with the isolated activated T- cells (10:1 effector: target ratio) and antibody, using 3-fold serial dilutions of antibody over a course of 3 hours at 37°C.
- PBMCs Peripheral Blood Mononuclear Cells
- CellTiter Glo® ATP catalyzed quantification
- the activation of PBMCs results in the release of cytokines, which drive cellular proliferation.
- Proliferation data was acquired using the following protocol: Human or cynomolgus monkey derived PBMC (5x10 5 / well) were incubated with a 3-fold serial dilution of anti-CD20xCD3 or Control antibody (including Control Ab 4 specific to CA9 antigen) in 96 well plates for 72 h at 37°C.
- Antibody 1 slgG4
- Antibody 2 slgG1
- Antibody 1 slgG4
- Antibody 2 slgG1
- the anti-CD3 x anti-CD20 bispecific antibodies having chimeric constant heavy chain regions slgG1 * (Antibody 3) and slgG4 * (Antibody 4) were analyzed using Surface Plasmon Resonance (SPR) (Biacore) technology to determine their kinetic binding parameters to human and cynomolgus Fey receptors.
- SPR Surface Plasmon Resonance
- CM-5 carboxymethyl dextran-coated
- CM-5 carboxymethyl dextran-coated
- 140RU-376RU of His-tagged human or monkey FcyR proteins were captured on the anti-penta-histidine amine-coupled CM-5 chip and stock solutions of antibodies were injected at 20 ⁇ /min for 2.5 min over the captured proteins.
- mAb binding response was monitored and, for low affinity receptors, steady-state binding equilibrium was calculated.
- slgG1 * and slgG4 * bispecific antibodies display no binding to human FcyRI, compared to antibodies having the wild-type (wt) hlgG1 or hlgG4-CPPC CH region.
- Chimeric heavy chain antibodies of this invention also display weak to no binding for several of the low-affinity FcRy receptors (e.g. FcRylla, FcRyllb) compared to antibodies with wt hlgG1 or hlgG4-CPPC Fc sequence (Table 11 ).
- Example 8- lgG1 and lgG4 antibodies having chimeric CH regions show decreased effector function in CDC assay
- Antibodies with chimeric CH regions were generated to produce mAbs with altered or reduced effector function.
- amino acid substitutions in the CH region may hinder the ability of an Ig Fc to bind to its receptor.
- signaling and immune responses such as B cell activation or phagocytosis, may be altered.
- the effect of amino acid modifications in the CH region on complement dependent cytoxicity (CDC) (in this example) and antibody-dependent cytoxicity (ADCC) effector function was examined.
- % cytotoxicity ((L S - L S R)/(L M R-L S R))*100% where L S R is baseline target cell luminescence and I_MR is maximal calcein release from cells lysed by digitonin.
- the EC 50 for cytoxicity was determined using Prism software (GraphPad). Values were calculated using 4-parameter non-linear regression analysis and are shown in Table 12, and Figures 10A and 10B.
- Table 12 slgG1 * and slgG4* antibodies display reduced activity in CDC assays measuring effector function
- Example 9- lgG1 and lgG4 antibodies having chimeric CH regions show decreased effector function in ADCC assay
- the toxicokinetic profile of Antibody 3 also known herein as slgGT
- Antibody 4 also known herein as slgG4 *
- slgGT serum samples
- Antibody 4 also known herein as slgG4 *
- Plasma samples for toxicokinetic analysis of total drug concentrations in serum were collected pre-dose and post-dose at 5 minutes, and 5, 24, 48, 72 and 168 hours, and Day 14, 21 , 35, 49, 66 and 84.
- the resultant serum samples were analyzed by a direct enzyme linked immunosorbent assay (ELISA) to determine the total drug concentration of the slgG1 * or slgG4 * antibody.
- ELISA direct enzyme linked immunosorbent assay
- Table 14 Pharmacokinetic Profile of Chimeric Antibodies in Serum of Cynomolgus monkeys Following a Single Intravenous Infusion to Cynomolgus Monkeys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015017778-6A BR112015017778B1 (en) | 2013-02-01 | 2014-01-31 | ANTIBODIES COMPRISING CHIMERIC CONSTANT DOMAINS |
MX2015009502A MX360746B (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains. |
AU2014212148A AU2014212148B2 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
EP18179622.8A EP3406634B1 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
EA201591407A EA032960B1 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
ES14706169.1T ES2687866T3 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
SG11201505072RA SG11201505072RA (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
EP14706169.1A EP2951207B1 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
KR1020157021205A KR102229732B1 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
JP2015556172A JP6422445B2 (en) | 2013-02-01 | 2014-01-31 | Antibodies containing chimeric constant regions |
MYPI2018702010A MY189467A (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
EP24172994.6A EP4417624A2 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
CA2899457A CA2899457C (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
DK14706169.1T DK2951207T3 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising constant chimeric domains |
CN201480006932.5A CN104955844B (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
PL14706169T PL2951207T3 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
NZ710598A NZ710598A (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
IL239688A IL239688B (en) | 2013-02-01 | 2015-06-29 | Antibodies comprising chimeric constant domains |
ZA2015/04697A ZA201504697B (en) | 2013-02-01 | 2015-06-29 | Antibodies comprising chimeric constant domains |
HK16105851.9A HK1217955A1 (en) | 2013-02-01 | 2016-05-23 | Antibodies comprising chimeric constant domains |
AU2019200764A AU2019200764B2 (en) | 2013-02-01 | 2019-02-05 | Antibodies comprising chimeric constant domains |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759578P | 2013-02-01 | 2013-02-01 | |
US61/759,578 | 2013-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014121087A1 true WO2014121087A1 (en) | 2014-08-07 |
Family
ID=50156909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/014175 WO2014121087A1 (en) | 2013-02-01 | 2014-01-31 | Antibodies comprising chimeric constant domains |
Country Status (23)
Country | Link |
---|---|
US (4) | US9359437B2 (en) |
EP (3) | EP2951207B1 (en) |
JP (3) | JP6422445B2 (en) |
KR (1) | KR102229732B1 (en) |
CN (1) | CN104955844B (en) |
AR (1) | AR095115A1 (en) |
AU (2) | AU2014212148B2 (en) |
CA (1) | CA2899457C (en) |
DK (2) | DK3406634T3 (en) |
EA (1) | EA032960B1 (en) |
ES (1) | ES2687866T3 (en) |
FI (1) | FI3406634T3 (en) |
HK (1) | HK1217955A1 (en) |
HU (1) | HUE040415T2 (en) |
IL (1) | IL239688B (en) |
MX (2) | MX360746B (en) |
MY (2) | MY189467A (en) |
NZ (1) | NZ710598A (en) |
PL (1) | PL2951207T3 (en) |
SG (2) | SG11201505072RA (en) |
TW (2) | TWI682941B (en) |
WO (1) | WO2014121087A1 (en) |
ZA (1) | ZA201504697B (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077491A1 (en) | 2013-11-20 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
WO2015143079A1 (en) | 2014-03-19 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Antibody compositions for tumor treatment |
WO2016039796A2 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
WO2016081490A1 (en) | 2014-11-17 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
WO2016085889A1 (en) | 2014-11-24 | 2016-06-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
US9359437B2 (en) | 2013-02-01 | 2016-06-07 | Regeneron Pharmaceuticals, Inc. | Antibodies comprising chimeric constant domains |
WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
WO2016176341A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
WO2017053856A1 (en) | 2015-09-23 | 2017-03-30 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
US9657102B2 (en) | 2012-09-21 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
WO2017184831A1 (en) | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
WO2017184832A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
WO2018208625A1 (en) | 2017-05-06 | 2018-11-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
WO2021026409A1 (en) | 2019-08-08 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
WO2021030680A1 (en) | 2019-08-15 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
WO2021091953A1 (en) | 2019-11-05 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | N-terminal scfv multispecific binding molecules |
WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
WO2021142191A1 (en) | 2020-01-08 | 2021-07-15 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
WO2021231447A1 (en) | 2020-05-12 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Novel il10 agonists and methods of use thereof |
WO2021247779A1 (en) | 2020-06-03 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES |
EA039429B1 (en) * | 2015-05-13 | 2022-01-26 | Ридженерон Фармасьютикалз, Инк. | Methods for tumor treatment using cd3cd20 bispecific antibody |
WO2022235628A1 (en) | 2021-05-04 | 2022-11-10 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
WO2023004282A2 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
WO2023022965A2 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
US11655286B2 (en) | 2019-06-11 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
US11780907B2 (en) | 2018-01-26 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
WO2023205753A1 (en) | 2022-04-21 | 2023-10-26 | Regeneron Pharmaceuticals, Inc. | Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof |
WO2023220647A1 (en) | 2022-05-11 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
WO2023230594A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
WO2023235848A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
US11866502B2 (en) | 2020-10-22 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
WO2024040249A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
WO2024092038A2 (en) | 2022-10-25 | 2024-05-02 | Ablexis, Llc | Anti-cd3 antibodies |
WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
WO2024130175A2 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses |
WO2024138191A1 (en) | 2022-12-23 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
WO2024152014A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2947151A1 (en) | 2010-08-02 | 2015-11-25 | Regeneron Pharmaceuticals, Inc. | Binding proteins comprising vl domains |
WO2015035606A1 (en) | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
ES2762640T3 (en) | 2014-03-21 | 2020-05-25 | Regeneron Pharma | VL antigen binding proteins exhibiting different binding characteristics |
WO2015143414A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
EP3160505A4 (en) | 2014-07-03 | 2018-01-24 | BeiGene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
SG10201900571YA (en) | 2014-07-22 | 2019-02-27 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
SG11201701711VA (en) | 2014-09-16 | 2017-04-27 | Regeneron Pharma | Anti-glucagon antibodies and uses thereof |
PT3226897T (en) | 2014-12-05 | 2021-04-13 | Eureka Therapeutics Inc | Antibodies targeting b-cell maturation antigen and methods of use |
ES2966099T3 (en) | 2014-12-05 | 2024-04-18 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting B cell maturation antigen and uses thereof |
EP3227436A4 (en) | 2014-12-05 | 2018-06-20 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
US11191844B2 (en) | 2015-07-06 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
JOP20160154B1 (en) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof |
KR101712638B1 (en) * | 2015-08-19 | 2017-03-07 | 한국과학기술연구원 | System and method of controlling protein expression by using PAC-1 and doxycycline antagonist containing PCA-1 as an effective ingredient |
TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
TW202417497A (en) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | Antigen-binding proteins that activate the leptin receptor |
KR20180089497A (en) | 2015-12-04 | 2018-08-08 | 메모리얼 슬로안-케터링 캔서 센터 | Antibodies and methods for targeting FC receptor-like 5 |
RS64588B1 (en) | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
AR108377A1 (en) | 2016-05-06 | 2018-08-15 | Medimmune Llc | BISPECIFIC UNION PROTEINS AND ITS USES |
TWI822521B (en) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | Methods of treating skin cancer by administering a pd-1 inhibitor |
CN115304669A (en) * | 2016-06-08 | 2022-11-08 | 上海交通大学医学院 | Antibody heavy chain constant region sequences that enhance the activity of agonistic antibodies |
KR20240070728A (en) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | Anti-c5 antibodies and uses thereof |
WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
TW201815821A (en) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | Anti-zika virus antibodies and methods of use |
CN106191072A (en) * | 2016-08-04 | 2016-12-07 | 沈沭彤 | Recombination human source is fitted together to GcFc genetic fragment and fusion protein |
CA3034326A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
BR112019005641A2 (en) | 2016-09-23 | 2019-07-30 | Regeneron Pharma | ANTISTEAP2 ANTIBODIES, ANTIBODY-PHARMACEUTICAL CONJUGATES AND BIESPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND USES OF THE SAME |
LT3515946T (en) | 2016-09-23 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antibodies |
JP7042816B2 (en) | 2016-11-08 | 2022-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Antigen-binding protein that antagonizes the leptin receptor |
TWI782930B (en) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof |
US10736976B2 (en) | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
MA47456A (en) | 2017-02-10 | 2019-12-18 | Regeneron Pharma | RADIO-LABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
CN114989305A (en) * | 2017-03-31 | 2022-09-02 | 北京智仁美博生物科技有限公司 | Novel bispecific antibodies and uses thereof |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
JP2020522254A (en) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | Multispecific molecules that bind myeloproliferative leukemia (MPL) proteins and uses thereof |
KR20200020902A (en) | 2017-06-26 | 2020-02-26 | 베이진 엘티디 | Immune treatment for hepatocellular carcinoma (HCC) |
CA3066779A1 (en) | 2017-06-28 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof |
US10730944B2 (en) | 2017-07-24 | 2020-08-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
TW201919582A (en) | 2017-07-24 | 2019-06-01 | 美商再生元醫藥公司 | Stabilized antibody compositions and methods of producing same |
TWI799432B (en) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | Anti-ctla-4 antibodies and uses thereof |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
CA3076632A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
KR20200116077A (en) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | Chimeric antigen receptor and coding polynucleotide specific for B cell maturation antigen |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
WO2019118556A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
CN111542540A (en) | 2017-12-18 | 2020-08-14 | 瑞泽恩制药公司 | Bispecific antigen binding molecules that bind leptin receptor and/or GP130 and methods of use thereof |
CN109971720B (en) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | Chimeric antigen receptor modified T cells targeting ErbB receptor family and uses thereof |
CN110054700A (en) * | 2018-01-18 | 2019-07-26 | 分子克隆研究室有限公司 | Long-acting treatment fusion protein |
EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
BR112020019026A2 (en) | 2018-03-24 | 2020-12-29 | Regeneron Pharmaceuticals, Inc. | GENETICALLY MODIFIED NON-HUMAN ANIMAL, METHODS FOR PRODUCING GENETICALLY MODIFIED NON-HUMAN ANIMAL, FOR GENERATION OF AN ANTIGEN-BINDING PROTEIN, FOR OBTAINING A NUCLEIC ACID, AND FOR OBTAINING A CELL THAT EXPRESSES AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE DOMAIN HUMAN IMMUNOGLOBULIN LIGHT CHAIN VARIABLE DOMAIN AND/OR HUMAN IMMUNOGLOBULIN, IN VITRO METHOD OF PRODUCTION OF HUMAN IMMUNOGLOBULIN VARIABLE DOMAIN, NUCLEIC ACID, HOST CELL, ISOLATED CELL, AND HUMINOGLOBULIN HEAVY CHAIN VARIABLE DOMAIN |
MX2020010547A (en) | 2018-04-06 | 2020-11-06 | Regeneron Pharma | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia. |
JP7328990B2 (en) | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Antibodies and bispecific antigen binding molecules that bind to HER2 and/or APLP2, and conjugates and uses thereof |
SG11202011232VA (en) | 2018-05-17 | 2020-12-30 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
KR20210022650A (en) | 2018-06-19 | 2021-03-03 | 리제너론 파아마슈티컬스, 인크. | Anti-factor XII/XIIa antibodies and uses thereof |
TW202005985A (en) | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies |
DE202019005887U1 (en) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
TWI838389B (en) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | BISPECIFIC ANTI-BCMAxANTI-CD3 ANTIBODIES AND USES THEREOF |
KR20210049863A (en) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | Anti-Fc epsilon-R1 alpha (FCERIA) antibodies, bispecific antigen-binding molecules that bind FCERIA and CD3 and uses thereof |
MX2021004284A (en) | 2018-10-23 | 2021-05-31 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof. |
SG11202102060PA (en) | 2018-11-21 | 2021-03-30 | Regeneron Pharma | Anti-staphylococcus antibodies and uses thereof |
EP3897841A1 (en) | 2018-12-21 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
AU2020214812A1 (en) | 2019-02-01 | 2021-09-23 | Regeneron Pharmaceuticals, Inc. | Anti-IL2 receptor gamma antigen-binding proteins |
CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
GB2598218B (en) | 2019-02-21 | 2024-05-08 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
EP3927745A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
WO2020172601A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
AU2020247803A1 (en) | 2019-03-22 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | EGFR x CD28 multispecific antibodies |
JP2022528804A (en) * | 2019-04-18 | 2022-06-15 | ジェネンテック, インコーポレイテッド | Antibody titer test |
SG11202111414RA (en) | 2019-04-24 | 2021-11-29 | Regenxbio Inc | Fully-human post-translationally modified antibody therapeutics |
JP2022537019A (en) | 2019-06-21 | 2022-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Use of Bispecific Antigen Binding Molecules that Bind PSMA and CD3 in Combination with 4-1BB Costimulation |
CN113993547B (en) | 2019-06-21 | 2024-04-26 | 瑞泽恩制药公司 | Use of bispecific antigen binding molecules binding MUC16 and CD3 in combination with 4-1BB costimulation |
CN114340684A (en) | 2019-09-16 | 2022-04-12 | 瑞泽恩制药公司 | Radiolabeled MET binding proteins for immunopet imaging |
BR112022007923A2 (en) | 2019-10-28 | 2022-07-26 | Regeneron Pharma | ISOLATED RECOMBINANT ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF IT, PHARMACEUTICAL COMPOSITION, POLYNUCLEOTIDE MOLECULE, VECTOR, CELL, AND METHOD TO PREVENT, TREAT OR IMPROVE AT LEAST ONE SYMPTOM OF INFLUENZA INFECTION |
AU2020398167A1 (en) | 2019-12-06 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
MX2022009769A (en) | 2020-02-11 | 2022-11-09 | Regeneron Pharma | Anti-acvr1 antibodies and uses thereof. |
CN111411079A (en) * | 2020-03-27 | 2020-07-14 | 北京时合生物科技有限公司 | Cell culture method, modified antibody, cell culture medium, cell product and application thereof |
WO2021217085A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
JP2023525034A (en) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | VEGF traps and minitraps and methods of treating eye disorders and cancer |
US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
CN116249718A (en) | 2020-08-26 | 2023-06-09 | 马伦戈治疗公司 | Multifunctional molecules binding to calreticulin and uses thereof |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
WO2022060915A1 (en) | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
CN116670170A (en) | 2020-09-15 | 2023-08-29 | 瑞泽恩制药公司 | Use of LEPR agonists for pain |
IL301037A (en) | 2020-09-18 | 2023-05-01 | Regeneron Pharma | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
WO2022072762A1 (en) | 2020-10-02 | 2022-04-07 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
JP2023547832A (en) | 2020-10-28 | 2023-11-14 | リジェネックスバイオ インコーポレイテッド | Vectored anti-TNF-α antibodies for ocular indications |
KR20230098176A (en) | 2020-10-29 | 2023-07-03 | 리젠엑스바이오 인크. | Vectorized TNF-alpha antagonists for ocular indications |
US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
CN116964101A (en) | 2020-12-18 | 2023-10-27 | 瑞泽恩制药公司 | Immunoglobulin binding NPR1 agonists |
TW202241943A (en) | 2020-12-29 | 2022-11-01 | 美商銳進科斯生物股份有限公司 | Tau-specific antibody gene therapy compositions, methods and uses thereof |
EP4284512A1 (en) | 2021-01-28 | 2023-12-06 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
JP2024517931A (en) | 2021-05-11 | 2024-04-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-TMPRSS6 antibodies and uses thereof |
CA3238750A1 (en) | 2021-11-24 | 2023-06-01 | Ella Ioffe | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
WO2023107957A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
WO2023133280A1 (en) | 2022-01-07 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
TW202400228A (en) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | Dosing regimens for mitigation of cytokine release syndrome |
WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023177772A1 (en) | 2022-03-17 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2023215806A2 (en) | 2022-05-03 | 2023-11-09 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
TW202417633A (en) | 2022-05-03 | 2024-05-01 | 美商銳進科斯生物股份有限公司 | Vectorized anti-tnf-α inhibitors for ocular indications |
WO2023224912A1 (en) | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
WO2023225098A1 (en) | 2022-05-18 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
TW202413434A (en) | 2022-08-02 | 2024-04-01 | 美商再生元醫藥公司 | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies |
WO2024076926A1 (en) | 2022-10-03 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
WO2024081180A1 (en) | 2022-10-10 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for reducing alloantibody levels in subjects in need of solid organ transplantation |
WO2024092133A1 (en) | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification |
WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
US20240158515A1 (en) | 2022-11-14 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
US20240262923A1 (en) | 2022-12-21 | 2024-08-08 | Genzyme Corporation | Anti-pd-1×4-1bb binding proteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (en) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | Antibodies with domain-denaturing constants |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU650629B2 (en) | 1989-08-09 | 1994-06-30 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994019935A1 (en) | 1993-03-09 | 1994-09-15 | Genzyme Corporation | Isolation of components of interest from milk |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5824543A (en) | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
KR970029803A (en) | 1995-11-03 | 1997-06-26 | 김광호 | Precharge Circuit of Semiconductor Memory Device |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
BR9908226A (en) | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Improvement of the circulating half-life of fusion proteins based on antibody |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
BR0008758A (en) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variants of parental polypeptides with altered effector function, polypeptides, isolated nucleic acid composition, vector, host cell, method for producing a polypeptide variant, method for treating a disorder in mammals and method for producing a variant fc region |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
DE60131456T2 (en) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
AU2002250293B2 (en) | 2001-03-09 | 2007-10-11 | Arnason, Barry G. Mr | Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors |
JP2005510470A (en) | 2001-09-28 | 2005-04-21 | エリューシス セラピューティクス,インコーポレーテッド | Methods and compositions for the prevention, diagnosis and treatment of cancer using bispecific molecules |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
CA2527878A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
DK1629011T3 (en) | 2003-05-31 | 2010-05-03 | Micromet Ag | Human anti-human DC3 binding molecules |
JP5068072B2 (en) | 2003-06-27 | 2012-11-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Modified binding molecule comprising a linking peptide |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
AR051836A1 (en) | 2004-11-30 | 2007-02-14 | Centocor Inc | RECEIVER ANTAGONISTS 3 SIMIL TOLL METHODS AND USES |
US20120189643A1 (en) | 2004-11-30 | 2012-07-26 | Carton Jill M | Toll Like Receptor 3 Antagonists, Methods and Uses |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
JP2009511067A (en) | 2005-10-14 | 2009-03-19 | メディミューン,エルエルシー | Cell presentation of antibody libraries |
EA016609B1 (en) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Recombinant monovalent antibodies and methods for production thereof |
US8075884B2 (en) | 2006-01-12 | 2011-12-13 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
ES2612118T3 (en) | 2006-03-15 | 2017-05-12 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by means of a complement inhibitor |
US8048421B2 (en) | 2006-03-23 | 2011-11-01 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
MX2009003393A (en) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor. |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
MX2009012343A (en) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto. |
EP3173484B1 (en) | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
WO2008145137A2 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
SG193868A1 (en) | 2007-09-26 | 2013-10-30 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
CL2008002885A1 (en) | 2007-09-26 | 2010-07-02 | Chugai Pharmaceutical Co Ltd | Anti-interleukin-6 (il-6) receptor antibody; and pharmaceutical composition that comprises it |
MX2010009190A (en) | 2008-02-20 | 2010-09-10 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES. |
CN102272161A (en) | 2008-11-06 | 2011-12-07 | 阿雷克森制药公司 | Engineered antibodies with reduced immunogenicity and methods of making |
SI3330293T1 (en) | 2008-11-07 | 2019-10-30 | Amgen Res Munich Gmbh | Treatment of pediatric acute lymphoblastic leukemia with bispecific antibodies against cd3xcd19 |
AR074438A1 (en) | 2008-12-02 | 2011-01-19 | Pf Medicament | PROCESS FOR THE MODULATION OF ANTAGONIST ACTIVITY OF A MONOCLONAL ANTIBODY |
US9085625B2 (en) | 2008-12-03 | 2015-07-21 | Genmab A/S | Antibody variants having modifications in the constant region |
AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
TWI544077B (en) | 2009-03-19 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | Antibody constant region change body |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
JP5837821B2 (en) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | Antibody constant region variants |
WO2011066501A1 (en) | 2009-11-30 | 2011-06-03 | Centocor Ortho Biotech Inc. | Antibody fc mutants with ablated effector functions |
US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
MX341925B (en) | 2010-03-29 | 2016-09-07 | Zymeworks Inc | Antibodies with enhanced or suppressed effector function. |
BR112012027917A2 (en) | 2010-04-30 | 2017-11-28 | Alexion Pharma Inc | antibodies that show reduced immunogenicity in a human individual |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
CN103249742B (en) | 2010-09-16 | 2017-04-12 | 巴利奥医药股份公司 | Anti-hutnfr1 antibody |
BR112013013311A2 (en) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | cytotoxicity-inducing therapeutic agent |
AU2011349719B2 (en) | 2010-12-23 | 2016-09-15 | Janssen Biotech, Inc. | Active protease-resistant antibody Fc mutants |
CN103476795B (en) | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | Antibody Fc variant |
CA2844540C (en) | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US20140370012A1 (en) | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
BR112014022692A8 (en) | 2012-03-14 | 2021-07-20 | Regeneron Pharma | multispecific antigen binding molecule |
EP2854523A1 (en) | 2012-06-05 | 2015-04-08 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
KR20150036606A (en) | 2012-07-13 | 2015-04-07 | 자임워크스 인코포레이티드 | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
US9714291B2 (en) | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
KR20150064068A (en) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE |
TWI682941B (en) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | Antibodies comprising chimeric constant domains |
IL290613B1 (en) | 2013-07-05 | 2024-07-01 | Genmab As | Humanized or chimeric cd3 antibodies |
US20160355588A1 (en) | 2013-07-12 | 2016-12-08 | Zymeworks Inc. | Bispecific CD3 and CD19 Antigen Binding Constructs |
CA3131724A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
MX2016008098A (en) | 2013-12-20 | 2017-01-11 | Hoffmann La Roche | Bispecific her2 antibodies and methods of use. |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
TWI701042B (en) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
JOP20160154B1 (en) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof |
MD3353212T2 (en) | 2015-09-23 | 2022-03-31 | Regeneron Pharma | Optimized anti-cd3 bispecific antibodies and uses thereof |
TWI756187B (en) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
BR112019005641A2 (en) | 2016-09-23 | 2019-07-30 | Regeneron Pharma | ANTISTEAP2 ANTIBODIES, ANTIBODY-PHARMACEUTICAL CONJUGATES AND BIESPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND USES OF THE SAME |
LT3515946T (en) | 2016-09-23 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antibodies |
TW202005985A (en) | 2018-06-21 | 2020-02-01 | 美商再生元醫藥公司 | Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies |
-
2014
- 2014-01-29 TW TW107120676A patent/TWI682941B/en active
- 2014-01-29 TW TW103103362A patent/TWI635098B/en active
- 2014-01-31 EP EP14706169.1A patent/EP2951207B1/en active Active
- 2014-01-31 NZ NZ710598A patent/NZ710598A/en unknown
- 2014-01-31 PL PL14706169T patent/PL2951207T3/en unknown
- 2014-01-31 MX MX2015009502A patent/MX360746B/en active IP Right Grant
- 2014-01-31 CA CA2899457A patent/CA2899457C/en active Active
- 2014-01-31 MY MYPI2018702010A patent/MY189467A/en unknown
- 2014-01-31 ES ES14706169.1T patent/ES2687866T3/en active Active
- 2014-01-31 EP EP18179622.8A patent/EP3406634B1/en active Active
- 2014-01-31 CN CN201480006932.5A patent/CN104955844B/en active Active
- 2014-01-31 HU HUE14706169A patent/HUE040415T2/en unknown
- 2014-01-31 JP JP2015556172A patent/JP6422445B2/en active Active
- 2014-01-31 SG SG11201505072RA patent/SG11201505072RA/en unknown
- 2014-01-31 MY MYPI2015001658A patent/MY176294A/en unknown
- 2014-01-31 EA EA201591407A patent/EA032960B1/en not_active IP Right Cessation
- 2014-01-31 FI FIEP18179622.8T patent/FI3406634T3/en active
- 2014-01-31 KR KR1020157021205A patent/KR102229732B1/en active IP Right Grant
- 2014-01-31 AU AU2014212148A patent/AU2014212148B2/en active Active
- 2014-01-31 WO PCT/US2014/014175 patent/WO2014121087A1/en active Application Filing
- 2014-01-31 AR ARP140100334A patent/AR095115A1/en unknown
- 2014-01-31 DK DK18179622.8T patent/DK3406634T3/en active
- 2014-01-31 EP EP24172994.6A patent/EP4417624A2/en active Pending
- 2014-01-31 SG SG10201706226QA patent/SG10201706226QA/en unknown
- 2014-01-31 US US14/170,166 patent/US9359437B2/en active Active
- 2014-01-31 DK DK14706169.1T patent/DK2951207T3/en active
-
2015
- 2015-06-29 IL IL239688A patent/IL239688B/en unknown
- 2015-06-29 ZA ZA2015/04697A patent/ZA201504697B/en unknown
- 2015-07-23 MX MX2018013738A patent/MX2018013738A/en unknown
-
2016
- 2016-05-05 US US15/147,791 patent/US10106610B2/en active Active
- 2016-05-23 HK HK16105851.9A patent/HK1217955A1/en unknown
-
2018
- 2018-09-12 US US16/128,907 patent/US10988537B2/en active Active
- 2018-10-15 JP JP2018193951A patent/JP6687702B2/en active Active
-
2019
- 2019-02-05 AU AU2019200764A patent/AU2019200764B2/en active Active
-
2020
- 2020-04-01 JP JP2020065490A patent/JP6895558B2/en active Active
-
2021
- 2021-03-30 US US17/217,567 patent/US20210246207A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
Non-Patent Citations (11)
Title |
---|
"IgG-Fc Engineering for Therapeutic Use", INVIVOGEN INSIGHT, 1 April 2006 (2006-04-01), pages 1 - 1, XP055115122, Retrieved from the Internet <URL:http://www.invivogen.com/docs/Insight200605.pdf> [retrieved on 20140424] * |
AKITO NATSUME ET AL: "Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 10, 15 May 2008 (2008-05-15), pages 3863 - 3872, XP007913550, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6297 * |
CANFIELD S M ET AL: "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483 - 1491, XP001181027, ISSN: 0022-1007, DOI: 10.1084/JEM.173.6.1483 * |
CHAPPEL M S ET AL: "IDENTIFICATION OF THE FC-GAMMA RECEPTOR CLASS I BINDING SITE IN HUMAN IGG THROUGH THE USE OF RECOMBINANT IGG1-IGG2 HYBRID AND POINT-MUTATED ANTIBODIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 88, no. 20, 1 October 1991 (1991-10-01), pages 9036 - 9040, XP002392092, ISSN: 0027-8424, DOI: 10.1073/PNAS.88.20.9036 * |
GREENWOOD J ET AL: "STRUCTURAL MOTIFS INVOLVED IN HUMAN IGG ANTIBODY EFFECTOR FUNCTIONS", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 23, no. 5, 1 January 1993 (1993-01-01), pages 1098 - 1104, XP009029660, ISSN: 0014-2980, DOI: 10.1002/EJI.1830230518 * |
INVIVOGEN: "IgG-Fc engineering for therapeutic use", INTERNET CITATION, 14 October 2007 (2007-10-14), pages 1 - 2, XP002616317, Retrieved from the Internet <URL:http://www.invivogen.com/ressource.php?ID=22> [retrieved on 20110112] * |
ROB C. AALBERSE ET AL: "IgG4 breaking the rules", IMMUNOLOGY, vol. 105, no. 1, 1 January 2002 (2002-01-01), pages 9 - 19, XP055115132, ISSN: 0019-2805, DOI: 10.1046/j.0019-2805.2001.01341.x * |
ROTHER R P ET AL: "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 12 December 2007 (2007-12-12), pages 1256 - 1264, XP002553743, ISSN: 1087-0156, [retrieved on 20071107], DOI: 10.1038/NBT1344 * |
ROUX K H ET AL: "Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE and IgA2, to form small immune complexes: Arole for flexibility and geometry", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 161, 1 January 1998 (1998-01-01), pages 4083 - 4090, XP002970810, ISSN: 0022-1767 * |
SALFELD JOCHEN G: "Isotype selection in antibody engineering", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, UNITED STATES, vol. 25, no. 12, 1 December 2007 (2007-12-01), pages 1369 - 1372, XP002668461, ISSN: 1546-1696 * |
XU Y ET AL: "RESIDUE AT POSITION 331 IN THE IGG1 AND IGG4 CH2 DOMAINS CONTRIBUTES TO THEIR DIFFERENTIAL ABILITY TO BLIND AND ACTIVATE COMPLEMENT", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269, no. 5, 4 February 1994 (1994-02-04), pages 3469 - 3474, XP002050452, ISSN: 0021-9258 * |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072656B2 (en) | 2012-09-21 | 2021-07-27 | Regeneran Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
US9657102B2 (en) | 2012-09-21 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
US11155621B2 (en) | 2012-09-21 | 2021-10-26 | Regeneran Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
US10106610B2 (en) | 2013-02-01 | 2018-10-23 | Regeneron Pharmaceuticals, Inc. | Antibodies comprising chimeric constant domains |
US10988537B2 (en) | 2013-02-01 | 2021-04-27 | Regeneren Pharmaceuticals, Inc. | Antibodies comprising chimeric constant domains |
US9359437B2 (en) | 2013-02-01 | 2016-06-07 | Regeneron Pharmaceuticals, Inc. | Antibodies comprising chimeric constant domains |
WO2015077491A1 (en) | 2013-11-20 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
EP3848395A1 (en) | 2014-03-19 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Antibody compositions for tumor treatment |
EP3594238A1 (en) | 2014-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Antibody compositions for tumor treatment |
CN106459214A (en) * | 2014-03-19 | 2017-02-22 | 瑞泽恩制药公司 | Antibody compositions for tumor treatment |
US11434300B2 (en) | 2014-03-19 | 2022-09-06 | Regeneron Pharmaceuticals, Inc. | Methods and antibody compositions for tumor treatment |
AU2015231295C1 (en) * | 2014-03-19 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Antibody compositions for tumor treatment |
AU2015231295B2 (en) * | 2014-03-19 | 2020-05-21 | Regeneron Pharmaceuticals, Inc. | Antibody compositions for tumor treatment |
EA035164B1 (en) * | 2014-03-19 | 2020-05-08 | Ридженерон Фармасьютикалз, Инк. | Antibody compositions for tumor treatment |
WO2015143079A1 (en) | 2014-03-19 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Antibody compositions for tumor treatment |
US10550193B2 (en) | 2014-03-19 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Methods and antibody compositions for tumor treatment |
WO2016039796A2 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
EP3604335A1 (en) | 2014-09-12 | 2020-02-05 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
AU2015350075B2 (en) * | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
JP2018505129A (en) * | 2014-11-17 | 2018-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Methods of treating tumors using CD3XCD20 bispecific antibodies |
WO2016081490A1 (en) | 2014-11-17 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
KR102614189B1 (en) * | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
US10662244B2 (en) | 2014-11-17 | 2020-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3XCD20 bispecific antibody |
KR20170089881A (en) * | 2014-11-17 | 2017-08-04 | 리제너론 파아마슈티컬스, 인크. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
EP4088572A1 (en) | 2014-11-24 | 2022-11-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
EP3689140A1 (en) | 2014-11-24 | 2020-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
WO2016085889A1 (en) | 2014-11-24 | 2016-06-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
WO2016161010A3 (en) * | 2015-03-30 | 2016-11-10 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
US11518807B2 (en) | 2015-03-30 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
AU2016242866B2 (en) * | 2015-03-30 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to FC gamma receptors |
WO2016176341A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
EA039429B1 (en) * | 2015-05-13 | 2022-01-26 | Ридженерон Фармасьютикалз, Инк. | Methods for tumor treatment using cd3cd20 bispecific antibody |
WO2017053856A1 (en) | 2015-09-23 | 2017-03-30 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
IL262268B2 (en) * | 2016-04-20 | 2024-05-01 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
IL262268B1 (en) * | 2016-04-20 | 2024-01-01 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
KR102474757B1 (en) * | 2016-04-20 | 2022-12-07 | 리제너론 파마슈티칼스 인코포레이티드 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
WO2017184832A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
US11512144B2 (en) | 2016-04-20 | 2022-11-29 | Regeneran Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing loci |
KR20210135340A (en) * | 2016-04-20 | 2021-11-12 | 리제너론 파마슈티칼스 인코포레이티드 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
WO2017184831A1 (en) | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
WO2018208625A1 (en) | 2017-05-06 | 2018-11-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
US11780907B2 (en) | 2018-01-26 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
US11655286B2 (en) | 2019-06-11 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
WO2021026409A1 (en) | 2019-08-08 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
WO2021030680A1 (en) | 2019-08-15 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
WO2021091953A1 (en) | 2019-11-05 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | N-terminal scfv multispecific binding molecules |
WO2021127495A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
WO2021142191A1 (en) | 2020-01-08 | 2021-07-15 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
WO2021231447A1 (en) | 2020-05-12 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Novel il10 agonists and methods of use thereof |
WO2021247779A1 (en) | 2020-06-03 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES |
US11866502B2 (en) | 2020-10-22 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
WO2022235628A1 (en) | 2021-05-04 | 2022-11-10 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
WO2023004282A2 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
WO2023022965A2 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
WO2023205753A1 (en) | 2022-04-21 | 2023-10-26 | Regeneron Pharmaceuticals, Inc. | Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof |
WO2023220647A1 (en) | 2022-05-11 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
WO2023230594A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
WO2023235848A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
WO2024040249A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
WO2024092038A2 (en) | 2022-10-25 | 2024-05-02 | Ablexis, Llc | Anti-cd3 antibodies |
WO2024107731A2 (en) | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
WO2024130175A2 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses |
WO2024138191A1 (en) | 2022-12-23 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
WO2024152014A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019200764B2 (en) | Antibodies comprising chimeric constant domains | |
JP6805130B2 (en) | CD123 binder and its use | |
EP3277725B1 (en) | Heavy chain constant regions with reduced binding to fc gamma receptors | |
KR20160010391A (en) | Recombinant bispecific antibody binding to cd20 and cd95 | |
BR112015017778B1 (en) | ANTIBODIES COMPRISING CHIMERIC CONSTANT DOMAINS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14706169 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 239688 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/009502 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2899457 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015556172 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015017778 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20157021205 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014706169 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014212148 Country of ref document: AU Date of ref document: 20140131 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201591407 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201505277 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 112015017778 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150724 |